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Ao meu avô, Antonio Carlos Gigliotti
“Uma busca começa sempre com a sorte de principiante, e termina sempre
com a prova do conquistador” (A quest always starts with beginner’s luck
and always ends with the trial of the conqueror)- Paulo Coelho, “O
Alquimista”
“Do or do not. There is no try”- Master Yoda
in “The Empire Strikes Back”
ABSTRACT
The cytokine IFN-γ is the architect behind an amazing immunological program of host
resistance to intracellular bacterial and protozoal infections. IFN-γ activates macrophages,
making them into inhospitable habitats for parasites attempting to grow inside them. The family
of obligate intracellular Gram-negative bacteria Chlamydia is an example of such pathogens.
The overall aim of this thesis was to unravel resistance to infection with the human respiratory
pathogen C. pneumoniae. Specific focus was placed on innate immune responses to
C. pneumoniae and the regulation and role of IFN-γ in the outcome of infection. An
experimental mouse model of lung infection and a macrophage model of in vitro infection were
used for this purpose.
A protective role for infection-induced IFN-γ in restricting C. pneumoniae growth in
vivo was observed, though IFN-γ was not required for resolution of infection. IL-12 and/or
IL-23 was a necessary but not an absolute requirement for expression of IFN-γ.
IFN-γ-dependent protection was in part mediated by iNOS expression. TNF-α, known to be
synergistic with IFN-γ, was not required for restricting Chlamydial growth. Innate immune cells
in the lung constituted an important source of IFN-γ and were essential for restricting
C. pneumoniae growth and for containment of bacteria in the lungs. However, NK cells were
not implicated in such protective IFN-γ release. On the other hand, lung macrophages isolated
from C. pneumoniae-infected mice expressed IFN-γ. Moreover,  bone marrow-derived
macrophages (BMMφ) conferred upon transfer to RAG-1-/-/IFN-γ-/- mice, enhanced resistance to
C. pneumoniae infection via their ability to release IFN-γ. Innate IFN-γ was however not
required for protection conferred by CD4+ or CD8+ T cells. Innate and T cell-derived IFN-γ are
also non-redundant (complementary) in protecting mice against C. pneumoniae.
C. pneumoniae-infected BMMφ also expressed IFN-γ in vitro. Such IFN-γ release was
IL-12-independent but required instead IFN-α/β  and restricted chlamydial growth. IFN-α/β,
and not IFN-γ, was required for iNOS-mediated protection in BMMφ. The molecular details of
BMMφ-derived IFN-γ expression revealed a TLR4-MyD88-dependent pathway of IFN-α and
IFN-γ induction. Also surprising was the presence of a TLR4- and MyD88-independent,
infection-induced NF-κB activation and pro-inflammatory cytokine expression.
Phosphorylation of STAT1 during infection was IFN-α/β-dependent, and necessary for
increased IFN-γ expression and for restricting Chlamydial growth. Expression of IFN-γ and
restriction of C. pneumoniae growth also required NF-κB activation, but such activation was
independent of IFN-α/β, revealing a dual pathway of C. pneumoniae-induced IFN-γ expression
in BMMφ: a TLR4-MyD88-IFN-α/β-STAT1-dependent pathway, and a TLR4-independent
pathway leading to NF-κB activation.
IFN-α/β was also protective in vivo by cooperating with IFN-γ for activation of
STAT1, which was required for restricting Chlamydial growth. Different from the in vitro
situation, IFN-γ was sufficient on its own for this effect and did not require IFN-α/β for its
expression.
In summary, IFN-γ is important for restricting C. pneumoniae growth. Innate IFN-γ is
protective both in lungs and in BMMφ. IFN-α/β are pivotal in regulating protective responses
in BMMφ, including IFN-γ release, but are dispensable for IFN-γ expression and protection in
vivo. This discrepancy may be a qualitative feature in C. pneumoniae pattern recognition by
different cell types; lung cells convey the generation of protective, IL-12-driven responses,
while IFN-α/β-driven protection in BMMφ is essential.
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ABBREVIATIONS
APC Antigen-presenting cell
BMMφ Bone marrow-derived macrophage
CAP Community-acquired pneumonia
CIITA Class II trans-activator
DC Dendritic cell
ds double-stranded
EB Elementary body
GAS γ-activated site
GPI Glycosylphosphatidylinositol
γcR Common cytokine receptor γ chain
HSP Heat-shock protein
ICE IL-1β-converting enzyme
IDO Indoleamine 2,3-dioxygenase
IFN Interferon
IFNAR1 α-chain of the IFN-α/βR
IFNAR2 β-chain of the IFN-α/βR
IFNGR1 α-chain of the IFN-γR
IFNGR2 β-chain of the IFN-γR
IκB Inhibitor of κB
IKK IκB kinase
IL Interleukin
iNOS Inducible nitric oxide synthase
IPC IFN-producing cell
IRAK IL-1R-associated kinase
IRF IFN regulatory factor
ISRE IFN stimulatory response element
JAK Janus kinase
LBP LPS-binding protein
LCMV Lymphocytic choriomeningitis virus
LPS Lipopolysaccharide
LRR Leucine-rich repeat
Mal MyD88 adaptor-like
MAPK Mitogen-activated protein kinase
MCMV Mouse Cytomegalovirus
MHC Major histocompatibility complex
MoPn C. trachomatis mouse pneumonitis agent
MPO Myeloperoxidase
MyD88 Myeloid differentiation factor 88
NF-κB Nuclear factor κ B
NK Natural killer
NO nitric oxide
NOD Nucleotide-binding oligomerization domain
NRAMP Natural resistance-associated macrophage protein
OAS 2’-5’ Oligoadenylate synthetase
PAMP Pathogen-associated molecular pattern
Phox NADPH Oxidase
PKR dsRNA-dependent protein kinase
Poly(I:C) Polyinosinic-polycytidylic acid
PRR Pattern-recognition receptor
R Receptor
RAG Recombination-activation gene
RB Reticulate body
SARM Sterile α and Armadillo motif
STAT Signal transducer and activator of transcription
TAP Transporter associated with antigen processing
TCR T-cell receptor
TICAM TIR-containing adaptor molecule
TIR Toll/IL-1R domain
TIRAP TIR-containing adaptor protein
TLR Toll-like receptor
TNF Tumor-necrosis factor
TRAF TNF receptor-associated factor
TRAM TRIF-related adaptor molecule
TRIF TIR-domain-containing adaptor inducing IFN-β
USF Upstream stimulatory factor
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INTRODUCTION
Living at the expense of someone else is a successful way of life, for a bug at
least, since infection is still the predominant cause of death in the world. Most
infectious diseases are caused by pathogens smaller than a single mammalian cell, so an
entire host encompasses a vast resource-abundant milieu for parasitism. Thus, a
mammalian host must invest heavily in generating cells dedicated to defense; cells of
the immune system. In maintaining a disease-free state, the immune system must first
recognize an invader and consequently deploy appropriate, multifaceted defense-
mechanisms which in an integrated fashion, will eliminate or curb pathogen growth.
The innate immune system is an evolutionarily conserved, ancient component
of host defense, present in both plants and animals (1). During a primary infection, the
pre-determined, fixed responses of innate immunity are the first to come into play. This
does not necessarily imply innate cell-mediated responses and could simply be the
action of epithelial barriers providing mechanical, chemical and microbiological
protection as well as the antibody-independent pathways of complement activation. In
mammals the cellular component of innate immunity consists of both myeloid and
lymphoid cells bearing germline-encoded receptors, i.e., of pre-determined
specificities; phagocytic cells (granulocytes, monocytes/macrophages and dendritic
cells [DCs]); lymphocytes lacking genetically-rearranged receptor specificities; Natural
killer (NK) cells, and lymphocytes lacking or displaying only poor genetically-
rearranged receptor specificities; T cells bearing γ:δ T-cell receptors (TCRs) and CD5+
(B-1) B cells. These cells have a swift, hard-wired response to infecting microbes,
serving as a first line of defense to prevent pathogens from establishing themselves in
the host. Sometimes, infecting microorganisms manage to subvert and overwhelm
innate immunity. The delayed but pathogen-specific clonal responses of the adaptive
immune system are then required for curbing pathogen growth, which often leads to
clearance of infection and memory to re-infection. The cells of the adaptive immune
system are lymphocytes bearing somatic rearranged receptors with randomly-generated
specificities, that are clonally distributed on individual cells. These are the thymus-
educated T cells expressing α:β TCRs together with either of the co-receptors CD4 or
CD8, and the CD5- (B-2) B cells expressing antibodies.
Signals are required for both alerting the host of infecting pathogens and for the
specific activation of lymphocytes. The innate immune system, which mediates
recognition of invading pathogens through their germline-encoded receptors, provides
both signals and is therefore central in the initiation of immune responses (reviewed in
(2)). This is mediated on the one hand through induction of pro-inflammatory cytokines
and chemokines (and thus inflammation) and on the other hand through antigen
presentation and induction of co-stimulatory molecules (and thus activation of adaptive
immunity). Cytokines are important not only in the initiation of the immune response,
but also for mediating the actions of T cells. In this respect, the Interferons (IFN)-α,
IFN-β and IFN-γ are important components of the immunological arsenal deployed
during an immune response. IFN-α/β act primarily during the innate and IFN-γ during
both the innate and adaptive phase of the immune response.
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The core of this thesis lies on the expression, regulation and role of particularly
IFN-γ in resistance to intracellular infection. The original articles reported herein focus
on the immune response against the most recently described member of the Chlamydia
family; Chlamydia pneumoniae, a human respiratory pathogen. Understanding
immunity to infection is the first step in vaccine design, and a thorough understanding
of the immune response against C. pneumoniae may unravel several aspects regarding
Chlamydial biology which may be useful in the eradication of not only C. pneumoniae
but of other Chlamydia too.
PATTERN RECOGNITION BY THE IMMUNE
SYSTEM
Innate immune recognition is special in that it mediates interactions between
products of different genomes where the host genome is constantly selecting against the
survival of the targets that it has evolved to recognize (2). Evolutionary pressure has
driven the effective recognition of structures that are essential for microbial survival,
i.e., attempting to vary these structures to avoid immune recognition could be lethal or
strongly disadvantageous for a microbe’s survival and growth. These structures are
termed pathogen-associated molecular patterns (PAMPs) and are shared by large
groups of pathogens. They are recognized by a relatively limited number of
germline-encoded receptors present on innate immune cells such as macrophages and
DCs (but also on surface epithelia and endothelial cells) termed pattern-recognition
receptors (PRRs). There are several families of PRRs and these can be cell-surface
expressed, present in intracellular compartments or humoral. The different family of
PRRs include C-type lectins, proteins containing a Leucine-rich repeat (LRR),
scavenger receptors, pentraxins, lipid transferases and integrins (reviewed in (3)).
PAMP recognition often leads to direct induction of effector functions such as
opsonization, complement activation, phagocytosis, apoptosis (reviewed in (3, 4)), but
also to the activation of pro-inflammatory signaling pathways, discussed below.
TLRs and Their Ligands
Toll-like receptors (TLRs) constitute a family of mammalian, closely related
transmembrane PRRs that respond to an array of microbial products (reviewed in (4-
6)). They are characterized structurally by an extracellular LRR domain and a
cytoplasmic Toll/IL-1R (TIR) domain (reviewed in (6, 7)). As derived from the name,
TIR domains are also involved in signaling downstream of the IL-1R and IL-18R,
which share many similarities with TLR signaling (reviewed in (7)). TIR domains also
play a role in plant host-defense, suggesting that they may be one of the first evolved
host-defense domains (8). It is unclear whether TLRs directly bind their particular
PAMPs, but a special feature of these PRRs is their function as signaling receptors.
TLRs mediate signal transduction events leading to induction of inflammatory
responses, such as production of pro-inflammatory cytokines, chemokines and
expression of co-stimulatory molecules. Thus, unlike other PRRs which seem mainly to
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mediate effector functions, the initiation of also adaptive immune responses can be
driven by TLR-dependent PAMP recognition.
The TLR family contains to date 10 members identified in mammals and those
TLRs with identified ligands are involved in the recognition of several important
PAMPs (reviewed in (9) and Figure 1). TLR2 recognizes the broadest range of PAMPs.
These include bacterial peptidoglycans (10, 11), the yeast cell-wall component
zymosan (12), glycosylphosphatidylinositol (GPI) anchors from Trypanosoma cruzi
(13) and mycobacterial lipoarabionomannan (14, 15). The broad specificity of TLR2
probably stems from the fact that it is able to pair with other TLRs, so far, TLR1 and
TLR6. Though not formally demonstrated, dimerization with either TLR1 or TLR6
seems to allow TLR2 to discriminate between di- and triacylated lipoproteins
(discussed in (5, 16)).
TLR3 recognizes double-stranded (ds) RNA and synthetic dsRNA, such as
polyinosinic-polycytidylic acid [poly(I:C)] (17). dsRNA is a specific viral product and
can be generated during the replication of both RNA and DNA viruses. Though not a
TLR, the cytosolic dsRNA-dependent protein kinase (PKR) also recognizes dsRNA
and is considered a PRR (discussed later).
TLR5 is the only TLR recognizing a protein ligand; flagellin (18). Flagellin is a
component of the flagellum found in both Gram-positive and -negative bacteria. While
flagellin is known to be a potent immunogen on which much of the clonal selection
theory was based, several factors explain why it is also a PAMP (reviewed in (19)).
These include the fact that flagellin is expressed in a highly repetitive pattern, elicits a
potent immune response even in plants and most importantly, the advantage of motility
for bacterial survival has presumably imposed structural constraints on flagellin
allowing it to be targeted by the innate immune system.
The natural ligands for TLR7, TLR8 and TLR10 have not been identified
(reviewed in (9)). Functional speculations have been made based on structural
homology to other TLRs with known ligands. TLR7 and TLR8 are highly homologous
to TLR9. TLR9 recognizes unmethylated CpG motifs in DNA (20), infrequent in
vertebrate genomes but very common in bacterial DNA. The ability of TLR7 to
recognize imidazoquinolines (21) as well as other synthetic compounds related to
nucleic acids, suggests that TLR7 (and possibly TLR8) may be involved in recognition
of microbial nucleic acid-like structures (reviewed in (6)). Similarly, TLR10 is related
to TLR1 and TLR6 and may thus be likely to pair with TLR2.
Figure 1: TLRs and Their Ligands.
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TLR4 Signaling
Lipopolysaccharide (LPS) is probably the most studied bacterial immunogen to
date, but it was not until recently that TLR4 was characterized as the signal-transducing
receptor for LPS. TLR signaling is described using LPS-mediated activation of TLR4
as an example (Figure 2). Accessory proteins are required for LPS signaling through
TLR4. LPS-binding protein (LBP), produced by the liver, is known to bind LPS via the
lipid-A moiety and this complex interacts with the GPI-anchored receptor CD14
(reviewed in (22)). Because CD14 lacks a cytoplasmic signaling domain, it serves
mainly to “recruit” LPS to TLR4. Studies indicate that TLR4 makes direct contact with
LPS (23-25). The small protein MD2, which associates with the extracellular part of
TLR4, has also been shown to be necessary for LPS-mediated TLR4 signaling (26).
The number of accessory proteins involved in TLR4 signaling suggest that the full
complement of molecules for a particular TLR to mediate recognition may be yet
uncharacterized for most TLRs, but it seems that TLRs most probably constitute the
signaling core of such complexes, as is the case for TLR4. The essential role of LBP,
CD14, MD2 and TLR4 in LPS-mediated signaling is confirmed by the
hyporesponsiveness of LBP-/-, CD14-/-, MD2-/- and TLR4-/- mice to LPS-induced
lethality (26-29).
Figure 2: Schematics of TLR4 Signaling. Details of MAPK signaling have been omitted for the sake of
simplicity but are known to promote pro-inflammatory cytokine release. Adapted from (5).
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Activation of NF-κB
The NF-κB family of transcription factors include the proteins p50, p52,
p65/RelA, RelB and c-Rel and are key regulators of immune responses (reviewed in
(30)). NF-κB transcription factors have a Rel homology domain which contains a
nuclear-localization sequence and is involved in DNA-binding, dimerization with other
Rel proteins and interaction with the family of inhibitors of NF-κB (IκB). The NF-κB
family is evolutionarily conserved with several homologs found in Drosophila
(reviewed in (31)). In unstimulated cells, they are found as cytosolic homo- or
heterodimers (primarily the combination of p50/p65). The IκB family includes IκB-α
(the main actor) as well as IκB-β, IκB-ε and Bcl-3. They associate with NF-κB dimers
and keep them sequestered in the cytosol. Upon stimulation, IκB become
phosphorylated, (on serine residues 32 and 36 for IκB-α) which target them for
ubiquitination and consequently degradation (reviewed in (32)). This allows the
otherwise IκB-sequestered NF-κB dimers to translocate from the cytosol into the
nucleus (33), where they bind to κB sites on target genes and mediate their
transcriptional induction. Several proteins have been shown to phosphorylate IκB and
thereby activate NF-κB, but the classical IκB-phosphorylating unit is the IκB kinase
(IKK) complex, constituted of IKK-α, IKK-β and a third regulatory subunit
IKK-γ/NEMO.
The generation of mice with targeted disruptions in members of the NF-κB and
IκB family have revealed many lethal phenotypes, but also enhanced susceptibility in
the non-lethal phenotypes of p50-/-, p52-/-, RelB-/-, c-Rel-/- and Bcl-3-/- mice to a variety
of viral, bacterial and parasitic infections (reviewed in (30)). Most deficiencies revealed
susceptibility to Listeria monocytogenes and Toxoplasma gondii infections. Due to the
multiple defects often found in these animals though, understanding how different
populations specifically contributed to susceptibility is difficult.
Upon PAMP recognition, the TIR domain of all known TLRs interacts with the
TIR domain present in the molecule myeloid differentiation factor (MyD) 88. This
cytosolic adaptor initiates a common signaling cascade that subsequently leads to
nuclear translocation of NF-κB. The same signaling steps are also known to occur upon
IL-1R or IL-18R engagement and in fact all proteins described for IL-1R signaling
have also been implicated in LPS signaling (reviewed in (7)). Via its death-domain,
MyD88 recruits IL-1R-associated kinase (IRAK)-1 and IRAK-2 (or in myeloid cells
IRAK-M) to the cytoplasmic tail of the receptor. The importance of MyD88 in
recruiting IRAK1 is confirmed in MyD88-/- mice, which also fail to activate NF-κB
following IL-1 or IL-18 stimulation (34). IRAK-1-/- mice also show severe ablation in
response to IL-1, IL-18 (35) and LPS stimulation (36). This ablation though, is not
complete for TLR responses and a newly described IRAK family member, IRAK4, has
been shown to be necessary for IL-1-, TLR2-, TLR3-, TLR4- and TLR9-driven
responses (37) and for activation of IRAK-1 itself (38), making it so far the IRAK
member most proximal to the receptor TIR domain.
Following IRAK recruitment, Tumor necrosis factor (TNF) receptor-associated
factor (TRAF) 6 becomes involved in the signaling cascade and consequently leads to
IKK-β activation, degradation of IκB, nuclear translocation of NF-κB and induction of
target genes involved in host defense. These include expression of pro-inflammatory
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cytokines (IL-1, IL-6 and TNF-α), chemokines, IFN-β, inducible nitric oxide synthase
(iNOS) and co-stimulatory molecules (reviewed in (31)).
Activation of MAP Kinase Cascade
Signaling downstream of TRAF6 also leads to activation of the mitogen-
activated protein kinase (MAPK) cascade (39). This is a complicated, multi-step
cytosolic cascade (reviewed in (40)) leading to activation of MAPKs that can
translocate to the nucleus and regulate gene expression. Two important MAPKs are p38
and c-Jun N-terminal kinase. These are involved primarily in cell proliferation and
differentiation, but also in inflammation. The overall importance of this pathway in host
defense is not fully understood.
MyD88-Independent Signaling
The expression of pro-inflammatory cytokines are absent in LPS-stimulated
MyD88-/- mice, but LPS-stimulated macrophages from the same display only an early
delay in the activation of NF-κB and MAPKs (41). This has been similarly shown for
LPS-stimulated MyD88-/- but not TLR4-/- DCs, which also retain the ability to
functionally mature, i.e., to up-regulate expression of co-stimulatory molecules (42).
Identical observations have been made for TLR3 signaling (17). Thus, except for pro-
inflammatory cytokine release, signaling through TLR3 and TLR4 proceed in the
absence of MyD88, suggesting that presence of other cytoplasmic adaptors in
mediating signaling by these TLRs (Figure 3). Today, four other TIR adaptor proteins
are recognized (reviewed in (43)). The TIR-containing adaptor protein (TIRAP), also
known as MyD88 adaptor-like (Mal), was initially thought to be the adaptor
responsible for TLR4-dependent, MyD88-independent signaling (44, 45). That fact that
LPS-induced DC maturation was intact in TIRAP-/- (46) and TIRAP-/-/MyD88-/- mice
(47) strongly suggests against a role for TIRAP/Mal in the MyD88-independent
pathway (47). LPS-stimulated MyD88-/- but not TLR4-/- macrophages have been shown
to express a set of IFN-α/β-inducible genes (48). Furthermore, LPS- and
poly(I:C)-dependent expression of IFN-β requires Interferon regulatory factor (IRF)3
(49, 50), activation of which was also intact in TIRAP-/-/MyD88-/- mice (47). Thus
IRF3, IFN-β and IFN-β-induced genes form part of the MyD88-independent response
during TLR3 and TLR4 signaling.
A third adaptor called TIR-domain-containing adaptor inducing IFN-β (TRIF)
(51), also known as TIR-containing adaptor molecule (TICAM)-1 (52) has recently
been reported. TRIF-/- mice (53) or mice with a chemically-induced mutation occurring
in the TRIF protein (54) showed severe impairment of TLR3- and TLR4-mediated
(late) NF-κB activation, including impairment of MyD88-independent responses, such
as expression of co-stimulatory molecules (55) and IRF3-induced genes (53, 54). Thus,
TRIF seems to mediate activation of IRF3 and the induction of IFN-α/β-driven
responses and mice with the chemically-induced mutation in TRIF were also highly
susceptible to mouse Cytomegalovirus (MCMV) infection (54). It is unclear why
TRIF-/- mice also had reduced expression of pro-inflammatory cytokines following
TLR4 stimulation (53), since this is considered an MyD88-dependent effect. A fourth
adaptor called TRIF-related adaptor molecule (TRAM) has recently been described to
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work with TRIF in TLR4-specific activation of IRF3 and NF-κB (45). TRAM-/- cells
also display impaired pro-inflammatory cytokine production following LPS stimulation
as well as impaired NF-κB and IRF3 activation (56). It seems therefore that
TRIF/TRAM work together with MyD88 for expression of pro-inflammatory
cytokines. The fifth TIR-containing adaptor is Sterile α and Armadillo motif (SARM)
(57), and though it has the characteristics of a signaling molecule, its function remains
unknown.
The fact that the host employs several accessory molecules for bringing LPS
and TLR4 together suggests that responding to LPS is a fine-tuned, complicated
process, but obviously important since so much effort is put into this. Similary, it is
unclear why so many different cytosolic adaptors are involved in LPS (and TLR3)
signaling. The dual nature of LPS may be part of the answer. Facing the (lethal) risk of
LPS-induced toxicity, the host still opts to respond to LPS and thus be able to recognize
and mount an immune response against invading, Gram-negative bacteria. In this
regard, possessing a signaling cascade with multiple adaptors also opens the possibility
for the host in fine-tuning its response to such an important but potentially lethal
immunogen. Because the recruitment of multiple adaptors allows response specificity it
is possible that the other TLRs strictly signaling through MyD88 may also turn out to
have other, as-yet undiscovered adaptors involved in fine-tuning their responses.
TLRs in Host Defense
The question whether or not responding to LPS was advantageous for host
resistance was addressed already some time ago with LPS-hyporesponsive C3H/HeJ
mice (58), which today are known to have a mutation in TLR4 (59). These animals
were reported to be more susceptible to infection with several Gram-negative bacteria,
(60-63). More recently, enhanced mortality was observed in TLR2-/- and MyD88-/- mice
Figure 3: Schematics of Adaptor Molecules Involved in Signaling Downstream of TLR3 and TLR4. TRIF
mediates MyD88-independent activation of IRF3, leading to release of IFN-β. Adapted from (56).
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to Staphylococcus aureus infection in comparison to WT controls (64). TLR2-/- mice
displayed enhanced mortality to Streptococcus pneumoniae due to reduced brain
bacterial clearance (65) and reduced control of Borrelia burgdorferi growth in tissues
(66).
The role of TLR signaling in parasitic infections has also been studied.
T. gondii-infected MyD88-/- mice displayed enhanced mortality associated to impaired
Interleukin (IL)-12 production by DCs (67), suggesting an important role for TLR
signaling in control of T. gondii, though the particular TLR(s) associated to IL-12
expression in vivo was not reported. A protective role for TLR2-dependent signaling
was recently demonstrated during Mycobacterium bovis (68) infection and a role for
TLR2 but particularly MyD88 in M. avium infection of mice (69). A delay in clearance
of two other lung pathogens, namely the Gram-negative bacterium Haemophilus
influenzae (70) and Respiratory syncytial virus (71) have also been shown. The latter
observation is particularly interesting, suggesting that TLR4 can recognize PAMPs
other than LPS, in this case the Respiratory syncytial virus fusion protein (71).
It is not always clear from the above studies whether the reported TLR
deficiencies are affecting the innate and/or the adaptive immune response. A role for
TLRs specifically in dictating the quality of adaptive immune responses has been
suggested (reviewed in (72)), and it is supported primarily by two studies. In the first
study, MyD88-/- mice immunized with ovalbumin in Freund’s complete adjuvant (a
strong inducer of IFN-γ) failed to induce antigen-specific IFN-γ and IgG2a but showed
unaffected IgE and IgG1 responses (73). On the other hand, immunization of
ovalbumin with alum (a strong inducer of IL-4) resulted in comparable levels of
antigen-specific IgG1 in MyD88-/- and WT mice (73). Thus, IL-4-driven responses may
either be dependent on other as-yet uncharacterized TLRs or other signaling PRRs, or
occur by default in the absence of TLR stimulation. The latter suggestion is supported
by the fact that MyD88-/- mice stimulated with a potent IFN-γ-inducing stimulant,
namely soluble tachyzoite extract from T. gondii, display a complete inability to mount
IFN-γ responses and instead display an IL-4 response (74). IL-12p40-/- mice stimulated
with the same extract did not produce IL-4 but displayed instead residual IFN-γ
production (74). This supports a more critical role for MyD88 signaling in promoting
IFN-γ responses rather than, as previously believed, IL-12 stimulation.
IFN-α/β
Sources of IFN-α/β
IFN-α/β were described almost 50 years ago (75), based on their ability to
“interfere” with viral replication, hence their name “interferon”. In both humans and
mice, there is only a single IFN-β, but 15 different IFN-α genes in humans and 10 in
mice. They are encoded by intronless genes and all bind to the same IFN-α/βR. Though
other related IFNs exist, such as IFN-δ in pigs, IFN-τ in cattle and sheep and IFN-ω in
cattle and humans, only IFN-α/β have been studied in detail (reviewed in (76, 77)).
Most cell types, including fibroblasts, macrophages and DCs, are capable of producing
IFN-α/β (reviewed in (77)). But the main IFN-α/β-producing cell (IPC) has been
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identified in humans (78) and in mice (79) as a rare type of DC with plasmacytoid
morphology. In the human setting, such IPCs have been shown to induce in vitro IFN-γ
production from naïve CD4+ T cells upon stimulation with virus (80). Though the latter
has not been demonstrated in mice, it is clear that mouse IPCs are a major in vivo
source of protective IFN-α production during MCMV infection (79) where endogenous
IFN-α/β are known to be protective (81). IFN-α is readily used in humans for the
treatment of various cancers (reviewed in (82-85)) and chronic hepatitis (reviewed in
(86)).
Biological Functions of IFN-α/β
Anti-Viral Effects
Though several immunoregulatory effects have been ascribed to IFN-α/β
(described below) the direct anti-viral effects that lead to their discovery are beyond
any doubt their hallmark. Several pathways of innate immunity have been described in
inhibition of viral growth, the best characterized are those involving Mx proteins, PKR,
and 2’-5’ Oligoadenylate synthetase (OAS) (reviewed in (76)).
Mx proteins are cytoplasmic GTPases specifically induced by
IFN-α/β.  Exactly how they inhibit viral replication is not fully understood. Mx1 was
discovered in the A2G mouse strain shown to have an inherent resistance to influenza
virus (87). Though Mx1 is functional in wild mice (88), it seems to be inactivated in
inbred laboratory strains (except for the A2G mouse). Thus, Mx proteins are not
involved in resistance to infection in experimental models, though cells transfected with
functional Mx or transgenic mice expressing functional Mx show enhanced resistance
to several viruses (reviewed in (89)).
PKR is a serine/threonine kinase mediating not only anti-viral activity but also
signal transduction such as activation of NF-κB through activation of the IKK complex
or phosphorylation of IκB-α (reviewed in (90)). PKR is transcriptionally induced
preferentially by IFN-α/β and enzymatic activation of the protein requires dsRNA,
making PKR a cytosolic PRR involved in recognition of dsRNA. PKR-dependent viral
growth inhibition entails the phosphorylation of the translation initiation factor eIF2,
resulting in its inactivation and consequently block of host protein synthesis, necessary
for viral replication (reviewed in (76, 91)).
As for PKR, OAS is transcriptionally induced by IFN-α/β and likewise
activated by dsRNA. Activated OAS uses ATP to produce short strings of 2’-5’-linked
(oligo) adenylates at the 3’ end of mRNA molecules. These are necessary in turn for
activation of RNAseL, which cleaves single-stranded RNA and consequently blocks
host transcription (reviewed in (76, 91)). The combined actions of PKR and OAS thus
result in the generalized inhibition of host translation and transcription which prevents
the assembly of new virus particles, inducing an anti-viral state in the
IFN-α/β-stimulated cell. Though PKR and OAS are classical IFN-α/β-regulated genes,
the may also be induced by IFN-γ. The importance of the PKR and OAS pathways in
resistance against viral infection is demonstrated by PKR-/-/RNAseL-/- mice which
display enhanced susceptibility to encephalomyocarditis virus (92). The large number
of viral-evasion proteins specifically targeting the PKR and OAS pathways (reviewed
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in (93)) further supports the protective role of IFN-α/β, PKR and OAS against viral
infections.
Immunoregulatory Effects
Enhancement of NK-cell cytotoxicity was one of the first described
immunoregulatory functions of IFN-α/β (94) as well as IL-2-independent NK-cell
proliferation (95). IFN-α/β have also been shown to promote bystander (i.e
TCR-independent) proliferation of memory CD8+ T cells (96) and to directly prevent
death of activated T cells (97). Activation of macrophages to kill Leishmania major has
also been shown through exogenous administration of IFN-α/β (98). In an experimental
system using a model antigen, maturation/activation of DCs by IFN-α/β has been
shown to promote T-cell proliferation and IFN-γ secretion, as well as antibody
production and isotype switching (99). Also involving DC stimulation, virus-induced
IFN-α/β was recently shown to mediate cross priming of CD8+ T cells (100). The use
of IFN-α/β as natural adjuvants in vaccine design has also been suggested from
findings made in an influenza vaccine model (101). This vast array of
immunoregulatory functions ascribed to IFN-α/β should imply a protective role for it
during most intracellular infections. It is therefore interesting to note that at least during
experimental infections, this does not seem to be the case. The use of IFN-α/βR-/- mice
has clearly confirmed the protective role of IFN-α/β during viral, but not bacterial or
protozoan infections (reviewed in (102)). It is possible however that in such animals,
one is only observing the effects of IFN-α/β on the innate response and not its
immunoregulatory role.
IFN-γ
Sources of IFN-γ
IFN-γ was first identified as a phytohemagglutinin (PHA)-induced,
IFN-α/β-like factor produced by lymphocytes able to block the cytopathic effects of
Sindbis virus (103). It has since then become a key player in immunity to infection
(reviewed in (102)) and a mediator of tumor immuno-surveillance (104). Unlike IFN-α,
mouse and human IFN-γ are each encoded by a single gene, unrelated to the genes
encoding IFN-α and IFN-β. IFN-γ signals through a heterodimeric IFN-γR present on
most nucleated cells.
IFN-γ is the architect behind an amazing immunological program governing
defense against most (if not all) intracellular infections (discussed below). Yet the
phenotype of mice with targeted deletions in IFN-γ, its receptor or components of the
receptor signaling machinery (reviewed in (91)), confirm that the effects of this
pleiotropic cytokine are confined to the immune system. This is also supported by the
phenotype of humans having deficiencies in IFN-γ (reviewed in (105, 106)). Thus,
IFN-γ is produced by cells of the immune system for the sake of an immune response.
The main cellular sources of IFN-γ are NK cells (107) of the innate and
activated CD4+ (108) and CD8+ (109) T cells of the adaptive immune system. The
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original monopoly of the above-mentioned lymphocytes on IFN-γ production has
recently been challenged. A series of independent studies (including those presented in
this thesis) show that different myeloid populations also express IFN-γ, discussed in
detail later.
Biological Functions of IFN-γ
Cellular response to IFN-γ can be viewed as an integrated “molecular program
of resistance” to intracellular pathogens (91). The fact that IFN-γ mediates resistance
primarily against intracellular bacteria and protozoa is confirmed by the enhanced
susceptibility of IFN-γ-/- or IFN-γR-/- mice to several experimental infections (reviewed
in (102), (110-115)). This is also demonstrated in Signal transducer and activator of
transcription (STAT)1-/- mice (116-118), which are also susceptible to viruses (119,
120). STAT1 is a molecule central to both IFN-α/βR and IFN-γR signaling (discussed
later). The importance of IFN-γ-mediated immunity is also supported by a rare human
immunodeficiency known as Mendelian susceptibility to mycobacterial infection. This
condition is characterized by genetic deficiencies in IL-12, IL-12R, IFN-γR and
STAT1, which often lead to fatal infections with otherwise atypical, non-pathogenic
mycobacteria and also enhanced susceptibility to salmonella (reviewed in (105, 106)).
These clinical findings clearly confirm the essential role of the IL-12-IFN-γ-STAT1
pathway in resistance against intracellular infections.
Some recent studies have employed the use of oligonucleotide microarrays to
analyze gene expression following IFN-γ stimulation (120-123). Differences in the
number of IFN-γ-responsive genes reported by these studies may reflect differences in
the oligonucleotide arrays, cut-off for fold induction/repression, cell type, concentration
of IFN-γ and time-point for analysis. One study using bone marrow-derived
macrophages (BMMφ) revealed a striking number of more than a 1000
IFN-γ-responsive genes (123). In this study, treatment with IFN-γ suppressed almost as
many genes as it induced, but a closer look revealed that genes directly related to
immunity and inflammation were more likely to be induced than repressed by IFN-γ.
This is in line with the general view that IFN-γ is a macrophage-activating factor (124,
125). In fact, the activation state of macrophages is an important determinant in the
outcome of intracellular infection. The biological consequences of IFN-γ are thus best
described in macrophages. These include antigen presentation by MHC class I and II,
induction of the respiratory burst enzyme NADPH Oxidase (Phox), induction of iNOS,
induction of tryptophan catabolism via Indoleamine 2,3-dioxygenase (IDO) and
induction of natural resistance-associated macrophage protein (NRAMP). Many of
these aspects are also applicable to other phagocytic and non-phagocytic cells and
overlap with actions of other cytokines.
Antigen Presentation
The expression of MHC class I and class II molecules following IFN-γ
stimulation was one of the first effects described for IFN-γ and involves a series of
molecules (reviewed in (91)). Though MHC class I is expressed constitutively on all
nucleated cells (except desidual trophoblasts), IFN-γ and to a lesser extent IFN-α/β can
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further enhance its expression. IFN-γ not only regulates actual expression of MHC class
I, but also of other components required for MHC class I antigen processing and
presentation. These include expression of β2 microglobulin, the transporter associated
with antigen processing (TAP)-1 and -2 and the proteasome regulatory subunits LMP2,
LMP7 and MECL1, which together generate the “immune” proteasome, better
equipped at generating peptides suitable for presentation on MHC class I. Expression of
MHC class II is restricted to professional antigen-presenting cells (APCs)
macrophages, DCs and B cells but is also strongly induced by IFN-γ. Unlike class I
induction, the class II pathway is regulated by a single IFN-γ-inducible transcription
factor, the class II trans-activator (CIITA). CIITA controls expression of both chains of
the MHC class II molecule as well as the accessory invariant chain and MHC
H-2M/HLA-DM.
Antimicrobial effector molecules Phox, iNOS, IDO and NRAMP
The respiratory burst is a well-characterized component of phagocyte resistance
that includes IFN-γ-regulated molecules. It involves a series of components in this case
those of the multi-enzyme Phox. Phox catalyzes the reduction of molecular oxygen to
superoxide anion, a highly reactive, antimicrobial oxygen species. Superoxide anion
can be converted by superoxide dismutase into hydrogen peroxide. Through another
respiratory-burst enzyme, myeloperoxidase (MPO), hydrogen peroxide can together
with chlorine ions form hypochlorous acid (bleach). There are (at least) seven
characterized subunits of the Phox, the cytosolic p40-phox, p47-phox p67-phox and the
GTPase Rac2, and the membrane-bound cytochrome C-forming components gp91-
phox, p22-phox and Rap1A (reviewed in (126)). Expression of p47-phox, p67-phox
and definitely gp91-phox have been reported to be regulated by IFN-γ (127-130),
sometimes in synergism with TNF-α (127, 129). Loss of function in Phox leads to
Chronic Granulomatous Disease, where patients suffer from bacterial infections and
IFN-γ therapy is often applied. The generation of p47-phox-/-, gp91-phox -/-, Rac2-/- and
MPO-/- mice confirm a protective role for the respiratory burst against primarily
bacterial infections but also against fungi (reviewed in (131)).
iNOS, an inducible isoform of NOS, catalyzes high-output,
calcium-independent production of nitric oxide (NO) gas (and L-citrulline) from
L-arginine and molecular oxygen. Like Phox, iNOS is also expressed in neutrophils
and macrophages but is induced by IFN-γ in many other cell types. NO is a highly
reactive and diffusible nitrogen radical with both anti-tumor and anti-microbial
activities (reviewed in (131-133)). NO interacts with superoxide anion to form the
highly toxic, antimicrobicidal molecule peroxynitrite. Cytokines, primarily IFN-γ and
TNF-α are potent inducers of iNOS, as are microbial products such as LPS (reviewed
in (132)). Since L-arginine is the only physiological substrate for iNOS, regulation of
its availability is rate-limiting for NO production as are co-factors for iNOS enzymatic
activity (reviewed in (134)). In various cell types including macrophages, IFN-γ
together with either TNF-α or LPS often leads to the co-induction of iNOS and such
rate-limiting enzymes (135-141). Thus IFN-γ seems not only involved in iNOS
expression, but also in orchestrating an overall cellular commitment for NO production.
The use of NO inhibitors or NO-generating compounds (reviewed in (132)) and iNOS-/-
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mice (reviewed in (131, 133)) have revealed an important role for iNOS-derived NO in
resistance to several intracellular bacteria, intracellular protozoa and viruses.
IDO catalyzes the conversion of L-tryptophan into L-kynurenine and is induced
by IFN-γ in various cell types including macrophages. By restricting the cellular pools
of L-tryptophan, intracellular parasites requiring this essential aminoacid for replication
are “starved”. Several studies show synergism for TNF-α in enhancing IFN-γ-mediated
IDO induction. IDO is clearly mediating in vitro growth control of T. gondii (142-146)
and Chlamydia species (147-152) though more recent findings also suggest an in vitro
growth-restricting role for IDO in Rickettsia conorii (153), CMV (154), S. aureus (155)
and Trypanosoma brucei (156) infections.
NRAMP was identified as the candidate gene for the Ity/Lsh/Bcg locus, which
was known to confer resistance against intracellular parasites such as Salmonella
typhimurium, M. bovis and L. donovani (157). Though constitutively expressed in
macrophages, NRAMP is enhanced by IFN-γ stimulation. NRAMP might be a
transporter in the phagolysosomal membrane of macrophages (158) but its exact
function is unclear.
Regulation of IFN-γ Production
Cross-linking of the TCR and co-stimulation are strong inducers of IFN-γ
expression in T cells (reviewed in (159)). APC-derived cytokines are the key inducers
for IFN-γ release from NK cells, but their role in enhancing IFN-γ production from
T cells is also appreciated.
Role of IL-12
IL-12 is the best characterized APC-derived cytokine involved in regulation of
IFN-γ production (reviewed in (160, 161)). This heterodimeric cytokine is composed of
an inducible p40 subunit and a primarily constitute p35 subunit, generating bioactive
IL-12p70. IL-12 was originally described as “NK-cell stimulatory factor” or “cytotoxic
lymphocyte maturation factor”, both products of Epstein-Barr virus-transformed human
B-cell lines that could activate NK-cell cytotoxicity (162, 163) and IFN-γ production
(162), as well as augment PHA-driven T-cell proliferation (162, 163) and IFN-γ
production (162). The ability of IL-12 to excel in IFN-γ production lies not only in its
efficiency at low concentrations, but also in its synergism with several other factors for
IFN-γ release. IL-12 is for example synergistic with cytokines such as IL-1, TNF-α and
IL-2 for IFN-γ expression from NK cells (162, 164, 165). Still, the best-described
synergism is that between IL-12 and IL-18, a cytokine related to IL-1 in terms of
structure, receptor family and function (reviewed in (166)). IL-18 is also produced by
APCs and like IL-1, must be cleaved by IL-1β-converting enzyme (ICE), also known
as Caspase-1, to be functional (167, 168).
IL-18 was described as an “IFN-γ-inducing factor” with the ability to induce
IFN-γ production from TCR-stimulated CD4+ T cells better than IL-12 itself, though it
also displayed synergism with IL-12 for IFN-γ production (169). This synergism
between IL-18 and IL-12 also applied to the generation of IFN-γ-producing CD4+ T
cells in vitro, but a role for IL-18 alone in this process was excluded (170). The
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inability of IL-18 to stimulate IFN-γ production in the absence of IL-12 was confirmed
by the fact that naïve T cells from IL-18-/- mice stimulated in vitro with IL-12 produced
IFN-γ similar to WT controls, while stimulation with IL-18 could not produce the same
result in T cells from IL-12p40-/- mice (171). Still, while TCR-stimulated CD4+ T cells
isolated from M. bovis-infected IL-18-/- mice produced IFN-γ in almost equal amounts
to WT controls, cells from IL-12-/-/IL-18-/- mice stimulated under similar conditions
failed to induce IFN-γ altogether, confirming also the co-operative action of IL-12 and
IL-18 on CD4+ T cells (171). Thus, IL-18 is alone a poor enhancer of IFN-γ but in the
presense of IL-12, stimulates synergistic IFN-γ release. This has been ascribed to the
fact that IL-12 up-regulates both chains of the IL-18R (172). Similarly, IL-18
up-regulates expression of IL-12Rβ2 in resting T cells (173), so that IL-12 and IL-18
work in concert to augment the responsiveness of cells for each other and consequently,
for the expression of IFN-γ.
It is possible that under certain circumstances, IL-18 may suffice for IFN-γ
production in the absence of IL-12. This is supported by a model using mice primed
with heat-killed Propionibacterium acnes. IL-18-/- mice primed with P. acnes and
consequently challenged with LPS display reduced levels of IFN-γ in the serum despite
normal levels of IL-12, as do T cells isolated from P. acnes-primed IL-18-/- mice
stimulated in vitro with anti-CD3 (171). Reduced serum levels of IFN-γ is also
observed in P. acnes-primed, LPS-stimulated ICE-/- mice (167, 168). Further support
for a distinct role for IL-12 and IL-18 in IFN-γ expression is a report analyzing the
transcriptional activity of the IFN-γ promoter in human CD4+ T cells. In transfected
CD4+ T cells, IL-18 was found to directly stimulate a luciferase reporter plasmid
coupled to the IFN-γ promoter while IL-12 could only do so in the presence of
TCR-stimulation (174), though it is unclear whether reporter activity truly reflects
IFN-γ production.
IL-12 also augments IFN-γ production following both TCR activation (175) and
co-stimulation via B7:CD28 interactions (176, 177). Thus for T cells, the fact that
APCs can deliver simultaneous cytokine and TCR stimulatory signals immensely
facilitates IFN-γ induction, though it is clear that IL-12 (nor IL-18) alone is enough for
substantial IFN-γ expression in T cells.
The overall importance of IL-12 in IFN-γ production is seen in IL-12p40-/- mice
which display reduced IFN-γ production by NK cells following LPS stimulation and
reduced IFN-γ but enhanced IL-4 production by T cells (primarily CD4+) following
immunization with a model antigen (178). STAT4 is the main transcription factor
mediating IL-12-driven transcription of IFN-γ (reviewed in (160)). In line with
IL-12p40-/- mice, STAT4-/- mice also displayed impaired IL-12-dependent IFN-γ
production and enhanced IL-4 responses (179), though interestingly, both IL-p40-/- and
STAT4-/- mice have residual (IL-12-independent) IFN-γ production. In fact, recent data
suggests that IL-12 is not an absolute requirement for IFN-γ production nor is its
absence responsible for enhanced IL-4 responses (74). The importance of IL-12 in
generating IFN-γ-dominated responses during different intracellular infections is
nevertheless well characterized (reviewed in (160, 161, 180)).
Two other IL-12-related cytokines have recently been described that add to the
complexity of IL-12-driven responses. IL-23 is composed of the IL-12p40 subunit and
a novel p19 subunit (181). It signals via a similar pathway to IL-12p70, using both the
IL-12Rβ1 chain and STAT4 (182), but is not as efficient in inducing IFN-γ expression.
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The other cytokine, IL-27 is composed of an IL-12p40-related molecule and a novel
p28 subunit (183). In comparison to IL-23, IL-27 is a potent inducer of IFN-γ in naïve
T cells but the role of either cytokine in promoting IFN-γ production in different
settings awaits further analysis.
Role of IFN-α/β
While IL-12 is required for induction of IFN-γ during intracellular bacterial and
intracellular protozoal infections, the same is not consistently true for viral infections
where IL-12p70 is not always detected (reviewed in (180)). During Lymphocytic
choriomeningitis virus (LCMV) and Vesicular stomatitis virus infections, IL-12 is
actually not required for induction of T cell-derived IFN-γ (184). Such observations
may be explained by the fact that IFN-α/β actually inhibit the production of IL-12 and
consequently IFN-γ production, both in vitro as well as during LCMV and MCMV
infections (185). Levels of IFN-α/β induced during MCMV infection are lower than
during LCMV, probably explaining why (early) IL-12-dependent, NK cell-derived
IFN-γ release is observed during MCMV (186, 187). In fact, inhibition of endogenous
IFN-α/β augments IL-12-driven responses during MCMV and allows the appearance
of early IL-12 and IFN-γ production during LCMV (185). The association between
high titers of IFN-α/β and reduced IFN-γ expression has also been suggested in mice
infected with hyper-virulent strains of M. tuberculosis (188).
While IFN-α/β are known to promote IFN-γ production from human T cells
(189), fewer studies report the same in mice. Direct support for this comes from LCMV
infection, where IFN-α/βR-/- mice cannot mount a protective CD8+ T-cell-derived
IFN-γ response even though an IL-12-dependent IFN-γ production attempts to
compensate for the absence of IFN-α/β-driven IFN-γ (190). Also, exogenous IFN-α/β 
have been shown to be potent stimulators of IFN-γ release from bone marrow-derived
NK cells when used in combination with IL-12 or IL-2, but not alone (191).
Interestingly, splenocytes from LPS-hyporesponsive C57Bl/10ScCr mice stimulated
with different heat-inactivated Gram-negative bacteria showed impaired IFN-γ
production (192). This effect could be reverted by addition of exogenous IFN-α or
IFN-β or by supplementing splenocyte cultures with WT C57Bl/10ScSn macrophages.
Though C57Bl/10ScCr mice do not express TLR4 (59) they are also defective in
IL-12R signaling (193). Thus, this study clearly supports an IL-12-independent
pathway for IFN-γ production in the experimental setting.
IL-18 has been shown to work together with IFN-α/β in the release of IFN-γ
from human NK and T cells (194, 195), from mouse splenocytes stimulated with
heat-killed, Gram-negative bacteria (196) and from CD8+ T cells during LCMV
infection (197). In fact, a previous discrepancy between human and murine cells in the
ability of IFN-α/β to stimulate IFN-γ through STAT4 activation has been challenged. It
was previously suggested that IFN-α/β were unable to synergize with IL-12 for
STAT4-dependent IFN-γ production in mice because of a minisatellite insertion in the
mouse STAT2 gene that disrupted the ability of IFN-α/β to activate STAT4 (198).
Now, not only has IFN-β been shown to activate STAT4 in Con A-activated mouse
splenocytes (196) but direct binding of STAT4 to the IFN-γ promoter (just like IL-12)
has been shown in IFN-α-stimulated splenocytes or in splenocytes from
LCMV-infected mice (199).
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Myeloid IFN-γ
Expression of IFN-γ by other populations other than NK or T cells has been an
issue of some controversy but is starting to gain acceptance. Actually the first reports
on macrophage-derived IFN-γ are not recent (200, 201). Few studies on myeloid IFN-γ
have been made using human material. Except for an isolated study showing that
human neutrophils secrete IFN-γ when stimulated in vitro with either LPS, IL-12 or
TNF-α (202), other studies essentially involve IFN-γ expression by alveolar
macrophages infected in vitro with M. tuberculosis (203), obtained from sarcoidosis
patients (204) or from bronchoalveolar lavage of patients with tuberculosis (205). The
overwhelming majority of studies were thus made with mouse cells and show that
IFN-γ can be produced in vitro by macrophages stimulated with LPS (206, 207), IL-12
(208), IL-12 and M. bovis (209), Legionella pneumophilia (210), IL-12 and IL-18 (211-
215) or IFN-γ itself (216). These studies have used a variety of macrophage
populations, including resting or thioglycollate-elicited peritoneal macrophages,
BMMφ and alveolar macrophages. A role for IL-12 in myeloid-derived IFN-γ
expression is also supported by studies with DCs. Splenic DCs infected in vitro with
L. monocytogenes produced IFN-γ in an IL-12-dependent manner (217). A role for
STAT4 in such IL-12-dependent DC and macrophage IFN-γ has also been reported
(213-215). Overall, these reports clearly suggest that IL-12 is an important factor for
myeloid-derived IFN-γ even though it was not until later that the IL-12R was formally
demonstrated on macrophages (212) or DCs (218). Furthermore, IL-12- and
IL-18-stimulated murine (219, 220) and human (221) B cells have also been reported to
express IFN-γ. It is clear that the sole combination of IL-12 and IL-18 suffices for
production of substantial amounts of IFN-γ from non-T cells.
The relevance of myeloid IFN-γ is nevertheless unclear. Few reports have
addressed its actual role during intracellular infection, even in vitro. Except for
T. gondii (214) and L. monocytogenes (217), the other pathogens used in studies of
myeloid IFN-γ (including C. pneumoniae in this thesis) have been respiratory
pathogens; Nocardia asteroides (222), mycobacteria species (205, 209) and
L. pneumophilia (210). Only during T. gondii and L. pneumophilia infection was the
involvement of IFN-γ in restricting pathogen growth studied. Though the biological
significance was not addressed, expression of myeloid IFN-γ was shown ex vivo during
N. asteroides, M. tuberculosis and L. monocytogenes. A protective role for IFN-γ in
vivo is well known in the latter two infections (110-112) as well as during
L. pneumophilia (223). The role of IFN-γ in protection against Nocardia is unknown
though a patient with inherited IL-12 deficiency had clinical N. asteroides infection
(224) and IFN-γ treatment of Chronic Granulomatous Disease patients suffering from
Nocardia infections protected patients against Nocardia dissemination (225).
Together with NK cell-derived IFN-γ, myeloid-derived IFN-γ might play an
important role in the innate response against infection (discussed in (226)). Further,
even small amounts of IFN-γ could suffice for induction of macrophage responses in
the absence of NK cells, and contribute to early pathogen containment. It seems logical
that IFN-γ, the prototypical macrophage-activating cytokine, should be produced in an
autocrine/paracrine fashion by macrophages themselves. As for DC-derived IFN-γ,
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since DCs may be important in governing the differentiation of T cells during an
immune response (227), DC-derived IFN-γ could possibly influence this process.
IFN-α/βR and IFN-γR Signaling
Since IFN-α/β and IFN-γ signal through related pathways that lead to some
overlap in gene expression, such signaling is addressed together. The details of
IFN-α/βR and (particularly) IFN-γR signaling have been extensively characterized
(reviewed in (76, 91, 228)). The IFN-γR is a heterodimeric receptor consisting of a
high-affinity, ligand-binding α-chain (IFNGR1) and a β-chain (IFNGR2) required for
signaling (Figure 4). Associated to the different receptor chains are Janus kinases
(JAKs), JAK1 binding to IFNGR1 and the β-chain of the IFN-α/βR (IFNAR2), JAK2
to IFNGR2 and Tyk2 binding to the α-chain of the IFN-α/βR (IFNAR1). JAKs are
associated to these receptor subunits even in the absence of ligand binding and are
essential for IFN-dependent responses. Bioactive IFN-γ works as a homodimer, binding
two IFNGR1 subunits. Less is known how IFN-α and IFN-β bind to IFNAR1, but for
both IFN-α/β and IFN-γ, ligand binding mediates aggregation of the different receptor
subunits, leading to the assembly of an active receptor complex. This in turn leads to
the activation of receptor-associated JAKs through auto- and trans-phosphorylation on
tyrosine residues and thus the initiation of intracellular signal transduction. Activated
JAKs phosphorylate in turn tyrosine residues on the cytoplasmic tails of the IFN-α/βR
and IFN-γR, creating docking sites for STATs. STATs are both signaling molecules
and transcription factors. In unstimulated cells, STATs remain in the cytosol but when
activated, transduce to the nucleus and activate transcription of target genes. STATs
contain SH2 domains and are therefore capable of recognizing phosphorylated tyrosine
residues. Upon receptor-tyrosine phosphorylation by JAKs, STATs, via their SH2
Figure 4: Schematic Diagram of IFN-α/βR and IFN-γR Signaling. See text and (76, 91, 228) for details.
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domains, dock onto the receptor and become activated by JAKs that phosphorylate
STATs at single tyrosine residues. This enable STATs to form complexes with each
other and adaptor proteins that together will dictate the DNA-binding ability of the
transcription factor.
Stimulation with IFN-γ leads to formation of primarily STAT1:STAT1
homodimers and stimulation with IFN-α/β leads to formation of STAT1:STAT2:IRF9
heterotrimers (reviewed in (76)). These transcription-factor complexes bind to distinct
elements in the promoters of IFN-responsive genes. STAT1 homodimers bind to
so-called IFN-γ-activated sites (GAS) while STAT1:STAT2:IRF9 heterotrimers bind to
IFN-stimulated response elements (ISREs). Overlap exists, and it is known that IFN-α
stimulation also leads to the formation of STAT1 homodimers and under certain
conditions, IFN-γ-activated STAT1 homodimers can interact with IRF9 that redirect
the STAT1 homodimers to ISRE sequences (229). However, duration and degree of
stimulation with a particular IFN and cell-type specificity affect the formation of the
particular type of STAT1-containing transcription factor, thus adding diversity to the
(genes induced and) responses elicited by IFN-α/β and IFN-γ.
STAT1-Independent Signaling
Confirming the central role of STAT1 in mediating IFN-α/β- and
IFN-γ-dependent responses, STAT1-/- mice were unable to manifest any biologic
responses to either IFN-α or IFN-γ (116, 119). In line, these animals also display
marked susceptibility to viral (116, 119), intracellular bacterial (116) and intracellular
protozoan infections (117, 118). It was surprising though, that IFN-γ was shown to
regulate gene expression even in the absence of STAT1 (230), revealing the presence
of IFN-γ-dependent but STAT1-independent signaling. Using oligonucleotide
microarrays, this alternative signaling pathway has been further studied in
IFN-γ-stimulated mouse embryonic fibroblasts (MEFs) (122) and IFN-α- or
IFN-γ-stimulated BMMφ (120). IFN-γ-dependent, STAT1-independent genes
expressed in MEFs required JAK1 and many are also known to be induced by
Platelet-derived growth factor, a potent inducer of cell proliferation (122). The fact that
some genes, like c-myc, were induced in STAT1-/- MEFs but repressed in the presence
of STAT1 further add to the regulatory diversity elicited by IFN signaling though a
biological relevance for such signaling remains to be clarified. Also, IFN-γ repressed
M-CSF-dependent proliferation of bone marrow cells in the presence but induced it in
the absence of STAT1 (120). A physiological relevance for IFN-dependent,
STAT1-independent signaling was demonstrated by the enhanced susceptibility of
IFN-α/βR-/-/IFN-γR-/- mice to both Sindbis and MCMV infections in comparison to
STAT1-/- mice (120). A relevant situation for STAT1-independent but IFN-dependent,
anti-viral responses may arise if STAT1 activation is blocked by viruses, as reported
during measles (231) and human papillomavirus (232) infections. A final intriguing
finding on IFN-dependent, STAT1-independent signaling comes from LCMV-infected
mice where early production of IFN-γ is absent. An explanation for this is given by the
fact that in STAT1-/- but not WT mice, IFN-α/β stimulate LCMV-induced IFN-γ
release (233). These findings have however not been confirmed by others.
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CHLAMYDIA
Microbiology
The word “Chlamydia” comes from the Greek for “cloak-like mantle”, based on
the erroneous belief that the Chlamydial inclusion “cloaked” the nucleus of infected
cells (234). The genus Chlamydia consists of the four species, C. pneumoniae,
C. trachomatis, C. psittaci, and C. pecorum. Despite intra-species differences,
Chlamydia share some primary biological features (reviewed in (235)); I) Chlamydia
are obligate intracellular gram-negative bacteria; II) Chlamydia share a common,
developmental cycle; and III) Chlamydia share a similar genome organization. These
features consequently point towards a common immunobiology, addressed later.
Life Cycle
In being obligate intracellular parasites, host-cell entry is not an option but
rather a pre-requisite for survival (and disease). In meeting such requirements,
Chlamydia possess an unique, biphasic developmental cycle (reviewed in (235-237))
(Figure 5). It involves a small (100 to 200 nm) metabolically inactive, infectious form
called the Elementary body (EB) and a non-infectious, metabolically active, larger (500
to 1000 nm) form called the Reticulate body (RB). Surprisingly, many details
pertaining to this life cycle are unclear.
It is known that Chlamydia enter cells through endocytosis, pinocytosis and
phagocytosis. This process involves several Chlamydial molecules (reviewed in (236)),
including the most abundant Chlamydial surface protein, Major outer membrane
protein. It is also clear that membrane-bound EBs avoid (via uncharacterized
Figure 5: Chlamydia Life Cycle. See text and (235-237) for details.
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mechanisms) fusion with lysosomes (238-240) and then somehow differentiate into
RBs. RBs reside within an intracytoplasmic, parasitophorous vacuole, termed the
Chlamydial “inclusion”, which is the only environment known to support Chlamydial
replication. Sphingomyelin from the host-cell exocytic pathway seems to accumulate
on the inclusion surface (241), making the inclusion into a “modified” Golgi-derived
vesicle which is retained intracellularly (reviewed in (242)). It has long been known
that Chlamydia contain needle-like projections, but it was not until sequencing of
Chlamydia genomes that the presence of a type III secretion machinery was confirmed
(243-246). This type III secretion system seems to be present in both EBs and RBs
(247). It supports the notion that Chlamydia are able to acquire nutrients from the
cytoplasm although the inclusion is not freely permeable (248) and are able to modify
the inclusion membrane so as to camouflage it into an exocytic vesicle. A recent
analysis of Chlamydial gene expression during the developmental cycle through the use
of oligonucleotide microarrays has suggested a role for a novel Chlamydial gene
homologous to human early endosomal antigen 1 (involved in endosomal trafficking
and fusion in mammalian cells) in avoiding phagolysosomal fusion (249).
After multiple rounds of replication, probably through binary fission, RBs
re-differentiate back into EBs that are released either through exocytosis or host-cell
lysis to initiate new rounds of infection. Only infectious EBs perpetuate the life cycle.
The length of the developmental cycle has been studied in vitro and may take 48h to
72h depending on the Chlamydial strain, host cell and environmental conditions.
Chlamydial Persistence
Persistence is defined as a long-term association between Chlamydia and the
host in which the organism remains viable, but in a culture-negative state (reviewed in
(250, 251)). It should not be confused with chronic infections where organisms are
actively replicating. All strains of Chlamydia may become persistent. Persistence has
not been specifically addressed in works presented in this thesis but the subject merits
discussion. Persistent infection in vitro seems to involve incomplete chlamydial growth,
if any. It has been suggested to be a developmental stage triggered as a consequence of
stress, such as during nutrient deprivation, elevated temperature or presence of IFN-γ.
Morphological criteria have been described for persistent forms of Chlamydia.
Stress-induced atypical inclusions are generally smaller in diameter and contain
RB-like aberrant bodies, larger in diameter than typical RBs. Such aberrant forms are
refractory to antibiotic treatment, since they are essentially non-replicative. Resumption
of growth and the eventual release of EBs is observed upon stress removal, leading to a
reorganization of the aberrant form into a replicative organism (Figure 5). The
mechanisms behind this shift are not known.
Aberrant Chlamydial inclusions express a special gene and protein profile
including lower levels of LPS, outer membrane proteins, genes involved in cytokinesis
and DNA replication and the up-regulation of stress-induced heat-shock protein
(HSP)-60 (252-254). HSP-60 colocalizes with macrophages in atherosclerotic plaques
(255), causes the production of pro-inflammatory cytokines by macrophages in vitro
(255-257) and the oxidation of low-density lipoprotein (258), which is involved in
atherosclerosis. Also, anti-HSP-60 immune reactivity correlates with the pathological
consequence of Chlamydial infections (reviewed in (259, 260)). Recently, the use of
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oligonucleotide microarrays has revealed an even more detailed picture of the
Chlamydial gene expression profile during IFN-γ-mediated persistence in vitro (261). It
gives firm support for the idea that the Chlamydia “persistence stimulon” is more than a
just a simple stress response, but rather a global response permitting bacterial survival
via an alternative developmental stage.
Evidence for Chlamydial persistence has also been documented in vivo during
C. pneumoniae infection (262), during genital infection with the C. trachomatis mouse
pneumonitis agent (MoPn) (263) and lung infection with a C. trachomatis trachoma
strain (264). Mice which have been previously infected intranasally with
C. pneumoniae or genitally with MoPn, were allowed to resolve primary infection, i.e.,
to become culture-negative for Chlamydia, and were then treated with a
immunosuppressant such as cortisone which caused the re-activation of infection,
suggesting that the organisms had become “ culture-negative” but were still present and
viable in vivo. It is therefore unclear during Chlamydia infections, if the reduction in
culturable Chlamydia observed as the infection starts to subside is actually a sign of
clearance of the organism by the host or simply the induction of persistence.
Though persistence has long been recognized as a major factor in the
pathogenesis of Chlamydial disease (reviewed in (250)), atypical aberrant forms have
only been associated with persistence in vitro. Re-activation of Chlamydia infection in
mice, though supportive of persistence, does not imply that aberrant forms are actually
present in vivo during the persistent stage of infection. Recently, atypical inclusions
could be cultured from C. trachomatis-infected patients refractory to antibiotic
treatment and in two individuals, atypical C. trachomatis inclusions were also detected
in vivo by electron microscopy (265). Although one cannot draw too many conclusions
on this small sample size, it is the first line of evidence that atypical, aberrant forms of
Chlamydia also exist in vivo.
Chlamydia Infections
Chlamydia are among the most widespread bacterial pathogens in the world,
causing different afflictions characterized by asymptomatic infection to late-stage
disease in humans and animals (reviewed in (236)). C. trachomatis and C. pneumoniae
are human pathogens while C. pecorum infects cattle and C. psittaci infects birds
(occasionally causing zoonosis in humans). Below the waist, C. trachomatis serovars
(strains) D to K are major causes of sexually-transmitted disease worldwide, with
pathological complications such as pelvic inflammatory disease and its sequelae,
ectopic pregnancy or tubal infertility. Above the waist, C. trachomatis serovars A to C
are agents of ocular disease, causing conjunctivitis and trachoma, the most common
cause of preventable blindness worldwide. Systemic disease caused by C. trachomatis
Lymphogranuloma venerum strains occur, but are not as common. While primary
C. trachomatis infections are often asymptomatic, tubal and ocular scarring are the
long-term consequences of persistent (or recurrent) infections.
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C. pneumoniae Respiratory Tract Infections
C. pneumoniae was first isolated in 1965 from the conjunctiva of a Taiwanese
child, identified as a human respiratory pathogen in 1986 and finally established as a
separate species of Chlamydia in 1989 (reviewed in (266)). Sero-prevalence of over
50%, observed worldwide, is reached by age 20 and continues to rise with age,
reaching approximately 75% in the elderly (reviewed in (266)). C. pneumoniae is today
recognized as an “atypical” agent of community-acquired pneumonia (CAP),
associated in 6 to more than 20% of cases, ranking often as the third most common
etiological agent (reviewed in (267)). The incidence of C. pneumoniae-related
bronchitis is lower, approximately 5% (reviewed in (237)) while incidences as high as
25% have also been reported (268). Less well characterized are the associations of
C. pneumoniae to pharyngitis (269), otitis (270) and sinusitis (271).
There are no obvious clinical manifestations specific to C. pneumoniae-induced
respiratory tract infections (reviewed in (237, 266, 272, 273)), except for possibly
chronic cough. Shortness of breath has also been reported (274). Transmission is
probably from person-to-person, via respiratory secretions (275). Sero-epidemiological
studies in family settings suggest that transmission is relatively inefficient (276). It is
estimated that approximately 70% of C. pneumoniae respiratory infections are mild or
asymptomatic, with 30% causing upper and lower respiratory disease, including CAP
(reviewed in (237)). Infection may present itself as biphasic, starting often with upper
respiratory involvement, usually pharyngitis, which may regress and be followed weeks
later by a cough and lower respiratory affliction. Though C. pneumoniae causes disease
only in a minority of cases, pneumonia per se may be fatal and may require
hospitalization. Pneumonia (together with influenza) is the sixth leading cause of death
in the USA and C. pneumoniae is probably the second most common agent of CAP
requiring hospitalization (reviewed in (277)). Long-lasting, i.e., chronic, respiratory
disease due to C. pneumoniae has also been reported (278, 279) as well as epidemics in
schools (280, 281) and among military conscripts (282-284). In fact, the first epidemic
described was identified solely because of a routine radiographic tuberculosis survey
(285), supporting the often mild nature of the infection. Like C. trachomatis, severe
disease due to C. pneumoniae is rare but case reports reveal severe systemic disease
(273, 286), respiratory distress syndrome (287), multiorgan dysfunction (288, 289) and
fulminant pneumonia (290). Altogether, observations clearly highlight the importance
of C. pneumoniae as a respiratory pathogen.
Association Between C. pneumoniae and Atherosclerosis
The association between C. pneumoniae and atherosclerosis is undoublty one of
the most fascinating findings in the field. A Finnish sero-epidemiological study was the
first to coin an association between acute myocardial infarction and C. pneumoniae
serology (291). These findings were followed by direct demonstration (292) and even
isolation (293) of C. pneumoniae in atherosclerotic lesions. The significance of these
findings are however inconclusive. Several studies in experimental models and
antibiotic clinical trials have attempted to address this etiological issue. Infection of
rabbits with C. pneumoniae induced inflammatory changes in the aorta while treatment
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of the same with antibiotics prevented pathology (294). Similary, in two different
mouse models of atherosclerosis, C. pneumoniae infection accelerated disease
progression (295, 296).
The first clinical study analyzing the effect of antibiotic treatment on the
outcome of cardiovascular disease reported a decrease in adverse cardiovascular events
and mortality (297). A total of 13 other studies have since been performed (reviewed in
(298)). Despite many of these studies yielding positive results, all were limited by size,
short observation periods and short antibiotic therapy regimens. The WIZARD trial is
the only large, adequately powered, clinical trial that has been concluded. Even though
antibiotic-treated subjects had a statistically significant, 33% reduction in mortality and
myocardial infarction during the first 6 months of the study, the overall results were
negative. Treatment fall-off after 3 months of antibiotic therapy questioned whether the
duration of treatment was adequate or not. This has been taken into account in two
other large trials, ACES and PROVE IT, which include 1 to 2 years of antibiotic
treatment. These trials are estimated to be concluded by March 2004. Untill then, a role
for anti-C. pneumoniae therapy in atherosclerosis remains unsettled.
Experimental Chlamydia Infections
Infection with C. trachomatis
In comparison to other experimental mouse models of infection, relatively few
studies have addressed immunity to Chlamydia. Such studies have focused mainly on
infection with different serovars of C. trachomatis, particularly MoPn. This is a mouse
strain not naturally occurring as a human pathogen. Nevertheless, MoPn has been
extensively used as a model for both lung and genital-tract infection. Genital-tract
infection with MoPn closely resembles the human disease (reviewed in (299)). The use
of genetically-modified mice has helped dissect immunity to C. trachomatis infection
(reviewed in (299, 300)), and will serve later as a discussion basis for the results
presented in this thesis where C. pneumoniae infection has been used. At this point it
suffices to say that a protective role for CD4+ and CD8+ T cells and IFN-γ has been
reported during C. trachomatis infection (reviewed in (301).
Infection with C. pneumoniae
A mouse model for C. pneumoniae using the first described respiratory isolate
AR-39, has been described (302). Intranasal infection induced pneumonia in animals
and no differences in susceptibility were observed between the inbred mouse strains
(C57Bl/6, BALB/c and C3H/HeN) tested. The work presented in this thesis is based on
a similar C. pneumoniae lung model which uses the respiratory isolate Kajaani 6 (303).
This isolate was obtained during an epidemic outbreak in military garrisons in northern
Finland (304). Intranasal inoculation with 106 inclusion-forming units of Kajaani 6 (a
dose 3 times lower than for AR-39) induces similar pathological features as that
described for the original model, possibly suggesting that this Finnish isolate is slightly
more virulent. Still, whole genome sequence comparisons between different
C. pneumoniae isolates reveal little variation (245, 305). Also, when an atherosclerotic
isolate was compared to a respiratory one, no differences were found (293). Even
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though these comparisons were not between AR-39 and Kajaani 6, it still seems
plausible that different C. pneumoniae isolates should induce similar features in
experimental settings based on their high genomic conservation. The main discrepancy
between the two models is that systemic dissemination has been reported in WT mice
infected with AR-39 (306). Infectious dose may account for this, as it has only been
observed in the Kajaani 6 model following high-dose infection (303).
Characteristic observations (reviewed in (307)) made in both models include
the establishment of a patchy interstitial pneumonia, i.e., affected regions interspersed
among areas of normal tissue. Inflammatory infiltrates are first neutrophilic and later
mononuclear. Chlamydia is often detected in the inflammed areas (308). This response
is very similar to that observed during C. trachomatis lung infection (309). Bacterial
lung levels also correlate with the degree of lung pathology and active infection is
eventually resolved (with sequential ablation of lung pathology) in immunocompetent
mice, or bacteria are at least not culture-positive from lungs 60 days after infection
(302). Ultrastructural studies revealed the presence of Chlamydial inclusions
(containing EBs, intermediate forms and RBs) in both epithelial cells and macrophages,
as well as dividing RBs (308). The persistent form was not described. Such findings are
also recorded in the lungs of C. trachomatis-infected mice (310). The C. pneumoniae
mouse model seems consistent with human disease to the point that WT mice infected
via the respiratory route acquire a mild, non-lethal lung infection with ensuing
pneumonia. Protective immunity in this model has not been studied in any greater
detail.
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AIMS OF THIS THESIS
The general aim of this thesis was to characterize the immune response during
experimental C. pneumoniae infection. Specific aims were to:
I) Study the relative role of innate and adaptive immunity during Chlamydia
lung infection, with emphasis on the regulation and role of particularly
IFN-γ and IFN-α/β in protection.
II) Study the regulation and expression of cytokines in Chlamydia-infected
macrophages and their role in restricting Chlamydial growth.
III) Study pattern recognition and signal transduction pathways activated in
Chlamydia-infected macrophages.
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DISCUSSION OF OBTAINED RESULTS
The importance of IFN-γ in protective immunity to intracellular infections has
been addressed, as has the function of macrophages as important effectors (and even
producers) of IFN-γ-mediated responses. PRR-bearing macrophages in the lungs might
recognize invading C. pneumoniae and through these (and other) innate receptors
contribute to activation of effector mechanisms. Understanding the innate immune
interplay between macrophages and C. pneumoniae may be central for unraveling
immunity to this pathogen. Specific interest regarding IFN-γ and innate immunity to
C. pneumoniae is therefore emphasized in the discussion. It should be stressed that the
content of this section requires of the reader prior knowledge of Papers I to VI, since
for the sake of space, a summary of each work has been omitted.
IFN-γ in Resistance to C. pneumoniae Lung Infection
Role of IFN-γ in the Outcome of C. pneumoniae Infection (Papers I to III)
The single most concise observation made throughout the different studies, was
the protective role of endogenous IFN-γ during infection with C. pneumoniae. Lung
levels of C. pneumoniae were dramatically enhanced in IFN-γR-/- (Papers I, II & VI)
and IFN-γ-/- (Paper VI) mice compared to WT controls. Enhanced C. pneumoniae levels
and C. pneumoniae DNA were also observed in IFN-γR-/- BMMφ compared to WT
BMMφ (Paper IV). This seems obvious in light of the described massive anti-microbial
program regulated by IFN-γ. The susceptibility of IFN-γ-/- or IFN-γR-/- mice to various
intracellular bacteria, intracellular protozoa and some viruses also anticipates this result
(both discussed under Biological Functions of IFN-γ). Though IFN-γ-/-, IFN-γR-/- or
anti-IFN-γ-depleted mice also display enhanced susceptibility following MoPn (311) or
C. trachomatis genital strain (312, 313) infections, variations in susceptibility to IFN-γ
have however been reported. Whereas IFN-γ-/- mice developed more severe genital-tract
infections when C. trachomatis genital strain was used, minimal effects were noted on
resolution of genital infection with MoPn (314, 315). These differences were not
related to cytokine production in vivo, but rather to the differential susceptibility of the
strains to IFN-γ-mediated effector mechanisms in vitro (315, 316). Thus the mouse
virulent MoPn seems to have adapted to the inhibitory, species-specific effects of
IFN-γ. But reports do show a protective role for IFN-γ during MoPn lung infection
(317) and during MoPn genital infection in SCID mice (318).
Host-cell polarization state has also been shown to affect the degree of
IFN-γ-mediated inhibition. Larger quantities of IFN-γ are required for C. trachomatis
growth inhibition in polarized cells (319) and is suggested to be due to larger
intracellular pools of L-tryptophan, which cannot be produced by some Chlamydia
strains, in these cells (320).
Discrepancies have also been reported on the role of IFN-γ during primary
contra re-infection. Protection may for instance depend on genetic background, with
IFN-γ being protective during primary infection of C57Bl/6 but not BALB/c WT mice,
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but involved in protection of both strains during re-infection (321). Such differences
may however be due to the degree of success of the anti-IFN-γ depletion and have not
been confirmed in IFN-γ-/- mice. Using the same C. pneumoniae isolate, the results in
this thesis do not reveal differences between IFN-γR-/- mice on the 129Sv/Ev or
C57Bl/6 background although both carry the H-2b haplotype (Paper VI). In all, genetic
background does not seem to affect the study of C. pneumoniae infection in mice.
IFN-γ-Independent Resolution of Infection
While IFN-γ was clearly important for restricting bacterial growth in the lungs,
it was not required for resolving infection (Paper I, II & VI). This suggests the presence
of IFN-γ-independent mechanisms of protection involved in resolution of infection or
alternatively in inducing persistence. The 100% mortality observed in
Recombination-activation gene (RAG)-1-/-/IFN-γR-/- or RAG-1-/-/IFN-γ-/- mice, which is
not seen in IFN-γR-/- or IFN-γ-/- mice (Papers II & III) also clearly supports the
existence of T- and B-cell-dependent, IFN-γ-independent protection.
Unpublished observations from our laboratory reveal enhanced C. pneumoniae
levels in the lungs of B-cell-deficient µMT-/- (Igh6) mice at 24 but not 7 or 14 days after
infection in comparison to WT controls, suggesting a protective role for B cells later
during C. pneumoniae infection. These findings are further supported by µMT-/-/CD8-/-
mice which display higher susceptibility than µMT-/- or CD8-/- mice at 14 and 24 days,
suggesting that CD8+ T cells and B cells synergize in the resolution of infection (M. E.
Rottenberg, unpublished observations). Lung infection of µMT-/- mice with MoPn also
reveals enhanced susceptibility (322) though µMT-/- mice infected genitally with a
C. trachomatis genital strain do not (323, 324). While re-infection of µMT-/- mice has
not been published for C. pneumoniae, µMT-/- mice after genital infection with MoPn
are more susceptible to re-infection (325). When µMT-/- animals are also depleted of
CD4+ cells, they are unable to resolve secondary infection (326). In summary,
IFN-γ-independent mechanisms of protection exist during Chlamydia infection, are
probably important later during primary infection or during re-infection, and probably
involve antibody production.
Regulation of IFN-γ Expression During C. pneumoniae Infection (Papers II & VI)
It is already appreciated that IL-12 can regulate IFN-γ expression on several
immune cells (discussed under Regulation of IFN-γ Production: Role of IL-12). In light
of this, it seems obvious that genital infection of IL-12p40-/- mice with a C. trachomatis
genital strain, and genital or lung infection of IL-12p40-/- or anti-IL-12-depleted mice
with MoPn result in slight to dramatically increased susceptibility to infection, which
are associated to reduction in IFN-γ production (315, 327, 328). Similarly,
C. pneumoniae-infected IL-12p40-/- mice displayed enhanced susceptibility to infection
and reduced expression of IFN-γ in the lungs (Paper II). Similar observations have been
made with C. pneumoniae-infected, anti-IL-12-depleted mice (329). In all,
IL-12-dependent IFN-γ seems to be an important protective pathway elicited during
Chlamydia infections. The cellular source of this IL-12 in vivo is however not fully
studied during C. pneumoniae  infection and includes at least macrophages (Paper III).
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Administration of exogenous IL-12 also confers protection to naïve mice
against challenge with C. trachomatis and is paralleled by IFN-γ secretion in vivo (330,
331). Still, observations made in C. psittaci-infected mice suggest that despite the
necessity for IL-12 in inducing early IFN-γ production, IFN-γ but not IL-12 was
required for resolving infection (332). Similarly, while IL-12p40-/- and IFN-γR-/- mice
are both susceptible to C. pneumoniae compared to WT controls, IFN-γR -/- mice are
more susceptible than IL-12p40-/- (lacking both IL-12 and IL-23) animals (Paper II).
These findings suggest the presence of alternative, IL-12-independent pathways for
IFN-γ release during Chlamydia infection. IL-18 could be involved in such a response
and has been implicated in IL-12-independent IFN-γ release from CD4+ T cells in
T. cruzi-infected mice (333). STAT4-independent IFN-γ-mediated protection was also
observed in T. gondii-infected mice receiving exogenous IL-2 + IL-18 (334). Still,
during MoPn lung infection, IL-18-/- or ICE-/- mice did not display enhanced
susceptibility to infection though a slight reduction in IFN-γ production was observed
(328). During C. pneumoniae lung infection, ICE-/- mice seem to have a delayed
resolution of infection (A. Gigliotti Rothfuchs & M. E. Rottenberg, unpublished
observations), which is not observed in IL-12p40-/- mice (Paper II). This suggests a
dissociation between IL-12- and IL-18-driven responses in vivo with only a marginal
role for IL-18 in protection against Chlamydia. It also suggests an IL-12- and
IL-18-independent control of infection.
In line, a role for both IL-12- and IL-18-independent, IFN-γ-mediated
protection has also been observed during L. monocytogenes infection, so other factors
may govern IFN-γ expression even during bacterial infections (335). In such a
situation, it is possible that cytokines such as IFN-α/β, shown to regulate IFN-γ
expression mostly but not exclusively during viral infections, (discussed under
Regulation of IFN-γ Production: Role of IFN-α/β) may be involved. This however,
does not seem to be the case in C. pneumoniae infection since lungs from IFN-α/βR-/-
mice did not display diminished expression of IFN-γ or increased levels of
C. pneumoniae (Paper VI). Thus, the IL-12-independent stimulus of IFN-γ production
in the lungs of C. pneumoniae-infected mice is unclear. Still, infection of IL-12p40-/-
and IL-12p40-/-/IL-18-/- mice has not been compared and a role for other IL-12-family
members cannot be excluded.
IFN-γ-Mediated Effector Mechanisms in the Control of C. pneumoniae (Papers I to III)
As previously described, IDO is clearly implicated in IFN-γ-mediated in vitro
inhibition of Chlamydial replication, at least in human cells. Differences in
susceptibility of various Chlamydia strains to IFN-γ exist, and are ascribed to that
strain’s ability to acquire or synthesize L-tryptophan. The IFN-γ-sensititve
C. pneumoniae (150) lacks L-tryptophan biosynthesis genes (245, 246) as probably do
IFN-γ-sensitive C. trachomatis trachoma strains (315, 316) where partial sequencing
has revealed a truncation in a L-tryptophan biosynthesis gene (336). On the other hand,
L-tryptophan biosynthesis genes are present in MoPn and C. trachomatis genital strains
(244-246) which are more resistant to the actions of IFN-γ (315, 316). Thus,
L-tryptophan biosynthesis seems to be an adaptive virulence determinant in Chlamydia,
corroborating the importance of IFN-γ-dependent IDO in restricting Chlamydial
growth. Such a role for IDO in generating a persistent form of Chlamydia has been
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shown by the re-activation of infection upon addition of L-tryptophan to
C. trachomatis-infected, IFN-γ-treated cells (337).
During C. pneumoniae infection, IDO mRNA expression was only observed in
the lungs of RAG-1-/- mice, where levels of IL-12p40 and IFN-γ were much higher than
in WT controls. A clear requirement for IFN-γ in induction of IDO was shown by the
complete ablation of IDO transcripts in lungs of RAG-1-/-/IFN-γR-/- mice, which were
also extremely susceptible to infection. Findings from other experimental infections
where IFN-γ is important for resistance, have also correlated IDO expression to
protection. For example, IDO (but not iNOS) expression and L-tryptophan depletion in
the lungs of T. gondii-infected mice was dependent on IFN-γ (338). Similar data from
T. gondii infection showed that IDO expression, L-tryptophan degradation and
increased L-kynurenine formation occurred in the presence of IFN-γ and IRF-1 but not
TNFRp55 (339). Also, enhanced IDO expression is observed in the placenta of
L. monocytogenes-infected mice, expression of which is completely abrogated in the
absence of IFN-γ (340). Still, these findings do not strictly show a causative role for
IDO-mediated protection in experimental infections.
In mouse fibroblasts, epithelial cells and macrophages, iNOS was credited for
mediating IFN-γ-dependent inhibition of chlamydial growth (341-345) and iNOS-/-
mice showed a more severe pathology and increased dissemination following MoPn
infection (346). These observations are in agreement with the dramatically reduced
expression of iNOS in the lungs of C. pneumoniae-infected IFN-γR-/- mice and the
enhanced lung levels of C. pneumoniae recorded in iNOS-/- mice (Paper I).
IFN-γ-mediated, iNOS-dependent expression was also observed in the absence of T and
B cells (Paper II), suggesting that innate IFN-γ is important for inducing iNOS.
However, IFN-γ-mediated, iNOS-independent protection does occur since iNOS-/- mice
are more resistant than IFN-γR-/- mice Moreover, treatment of MoPn-infected cells with
IFN-γ also resulted in bacterial control in the absence of NO (347).
Similar to IDO, gp91-phox seems only to be induced as a compensation in the
lungs of C. pneumoniae-infected RAG-1-/- mice (Paper II). While presence of
gp91-phox was associated with IFN-γ-mediated protection in such animals, the
outcome of C. pneumoniae infection in gp91-phox-/- mice has not been evaluated.
Genital infection with MoPn in p47-phox-/- mice had no effect on susceptibility or
resolution of infection (348). Though superoxide-dependent inhibition of C. psittaci in
lymphokine-activated macrophages has been reported (349), other studies did not show
a reactive oxygen-dependent restriction of Chlamydial growth in IFN-γ-activated
epithelial cells (350) or macrophages (351). Thus, Phox is probably not involved in the
control of Chlamydia infection. Likewise, IFN-γ-mediated iron deprivation has been
suggested to control Chlamydial infections in vitro in some studies (352-354) but not
others (355).
Exogenous administration of certain antibacterial peptides to epithelial cells or
fibroblasts lead to the restriction of Chlamydial growth (356, 357), but it is unclear to
what degree IFN-γ regulates such processes. Another effector molecule probably not
involved in IFN-γ-mediated protection in C. pneumoniae is NRAMP. It was not
necessary for control of either C. pneumoniae, MoPn lung infection, or during in vitro
infection of macrophaes with MoPn or a Lymphogranuloma venerum strain of
C. trachomatis (358).
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An immunoregulatory role for IFN-γ during MoPn lung infection has been
suggested where IFN-γ-/- mice exhibited a partial IL-4-dependent immunopathology
together with disseminated infection (317). This role does not seem to apply to
C. pneumoniae infection where expression of IL-4 and IL-10 in the lungs of infected
IFN-γR-/- mice are similar to that of WT mice (Paper I). However, IL-13 expression and
C. pneumoniae levels were increased upon transfer of IFN-γ-/- CD4+ or IFN-γ-/- CD8+ T
cells into RAG-1-/-/ Common cytokine receptor γ chain (γcR)-/- mice, so a role for IFN-γ
in regulating the cytokine balance cannot be fully excluded (M. E. Rottenberg,
unpublished observations). IFN-γ might also modify the outcome of infection by
regulating chemokine expression (359). It is therefore possible that altered levels of
IFN-γ-regulated adhesion molecules or chemokines may account for quantitative
changes in the inflammatory infiltrate (reviewed in (91)), including the presence of
granulocytes mainly in the bronchial lumen (Paper II, data not shown). The relative role
of these mechanisms in Chlamydia infection is unknown.
The purigernic P2X7 nucleotide receptor expressed on macrophages and DCs is
known to mediate ATP-dependent killing of M. bovis (360) in a process that triggers
phagolysosomal fusion and is independent of Phox, iNOS and NRAMP (361).
Expression of P2X7R on monocytes has been shown to be synergistically up-regulated
by IFN-γ and TNF-α (362). Similar to Mycobacteria, ATP-dependent P2X7R signaling
has recently been shown to promote growth control of MoPn by triggering
phagolysosomal fusion in macrophages (363). This molecule is therefore a novel
candidate for IFN-γ-mediated, iNOS-independent control of C. pneumoniae.
Another novel IFN-γ-regulated mechanism is that of the growing family of
small GTPases, including IGTP, LRG-47, IRG-47 and TGTP (364). They localize to
the endoplasmic reticulum but their functions are unclear. Interestingly, IGTP-/- (365)
and LRG-47-/- and IRG-47-/- (366) mice displayed enhanced mortality to T. gondii, and
IRG-47-/- also to L. monocytogenes (366), while expressing intact levels of IL-12p40,
IFN-γ and iNOS. Further, LRG-47-/- but not IGTP-/- or IRG-47-/- mice have recently
been shown to be susceptible to M. tuberculosis in an iNOS-independent way and
susceptibility was associated to impaired phagosome maturation (367). Such GTPases
may be potential IFN-γ-inducible effectors in resistance to Chlamydia.
Cellular Sources of IFN-γ During C. pneumoniae Infection (Papers II & III)
IFN-γ secreted as a result of innate-immune responses is important for
restricting Chlamydial growth. This is demonstrated by the increased susceptibility of
MoPn lung-infected nude mice treated with anti-IFN-γ neutralizing antibodies
compared to undepleted nude controls (318) and the severe susceptibility of
C. pneumoniae-infected RAG-1-/-/IFN-γR-/- (Paper II) or RAG-1-/-/IFN-γ-/- (Paper III)
mice compared to RAG-1-/- controls. Such severe susceptibility in RAG-1-/-/IFN-γ-/- was
associated with the dissemination of C. pneumoniae infection into hearts, spleens and
livers (Paper III and data not shown), suggesting that innate IFN-γ is important for
restricting the spread of C. pneumoniae in vivo.
NK cells are known to participate in the resistance against a number of bacterial
and protozoan infections through their ability to secrete IFN-γ (reviewed in (368, 369)).
However, the involvement of NK cells in the control of Chlamydia infection is unclear.
During MoPn genital infection, anti-asialo-GM1-mediated NK-cell depletion lead to a
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reduction in early IFN-γ expression in the genital tract and though depletion had no
effect on bacterial levels early during infection, the course of infection was prolonged
in the treated group (370). Differences in bacterial levels early after infection in
anti-asialo-GM1-treated, MoPn lung-infected mice were also not observed in other
studies (371), but reduced lung levels of IFN-γ following anti-asialo-GM1 treatment in
SCID mice are recorded (318). Thus, NK cells seem to be a source of IFN-γ during
MoPn infection though a protective role early during infection, when NK cells would
be expected to act, is not reported.
On the other hand, anti-asialo-GM1-mediated depletion of NK cells in
C. pneumoniae-infected RAG-1-/- mice did not alter susceptibility to infection and only
a partial decrease in lung IFN-γ expression was observed (Paper II). This was in
contradiction with the general belief that NK cells are important sources of innate
IFN-γ during intracellular infections, an issue first described for L. monocytogenes
infection where a similar approach of anti-asialo-GM1 depletion was used (372). In
fact, this very same result has been challenged by findings showing that
anti-asialo-GM1-treated, L. monocytogenes-infected RAG-2-/- mice have intact IFN-γ
levels in the sera and that macrophages and DCs are important sources of innate IFN-γ
during infection (217). In line, NK1.1 depletion in RAG-1-/- mice resulted only in a
slight increase in susceptibility to L. monocytogenes (E. Eriksson, unpublished
observations). The role of NK cells as the main innate IFN-γ source in vivo has also
been challenged during S. typhimurium infection where granulocytes and macrophages
were shown to be the main source of IFN-γ during primary infection (373).
Despite that ablation of NK-cell cytotoxicity in spleens confirmed efficacy of
depletion in C. pneumoniae-infected RAG-1-/- mice, it could not be excluded that small
number of lung NK cells surviving treatment were responsible for the partially reduced
IFN-γ levels detected. To exclude this, γcR-/- mice which are deficient in IL-2R, IL-4R,
IL-7R, IL-9R, IL-15R and IL-21R signaling, were crossed with RAG-1-/- mice (Paper
III). γcR-/- mice have severe cellular abnormalities such as the lack of peripheral lymph
nodes, greatly diminished B- and T-cell numbers and a complete absence of NK cells
(374). There are many unanswered questions regarding NK-cell development, but in
vitro models suggest some degree of involvement for IL-2, IL-7, IL-15 and possibly
IL-21 (reviewed in (375)) in generation of NK cells. Because C. pneumoniae-infected
RAG-1-/-/γcR-/- and RAG-1-/- mice showed similar levels of IFN-γ and bacteria in the
lungs, it was possible to conclude NK cells were not required for IFN-γ expression in
these mice, and that innate γcR signaling was also not involved in protection in vivo
(Paper III). This finding confirms the previous study in NK cell-depleted RAG-1-/-
mice, where it was also shown that RAG-1-/-/Perforin-/- mice were as susceptible as
RAG-1-/- controls (Paper II). The combined data thus excludes the participation of NK
cells in protective innate immune (IFN-γ- and perforin-mediated cytotoxic) responses
against C. pneumoniae.
Further, bronchoalveolar lavage cells, F4/80+ and CD14+ macrophages isolated
from the lungs of C. pneumoniae-infected RAG-1-/- mice expressed IFN-γ (Paper III).
The protective role of this expression is suggested by the enhanced susceptibility of
either RAG-1-/-/IFN-γR-/- or RAG-1-/-/IFN-γ-/- mice to C. pneumoniae (Papers II & III).
Transfer of WT but not IFN-γ-/- BMMφ into C. pneumoniae-infected RAG-1-/-/IFN-γ-/-
mice protected them from infection (Paper III), clearly supporting a protective role for
macrophage-derived IFN-γ production in innate immune control of C. pneumoniae in
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vivo. IFN-γ secretion by lung macrophages has also been shown in vivo during
M. tuberculosis infection in mice as well as in M. tuberculosis-infected patients
(discussed under Regulation of IFN-γ Production: Myeloid IFN-γ). In vivo expression
of IFN-γ by granulocytes and macrophages has also been reported in
S. typhimurium-infected mice (373). Even though at this point the participation of other
non-lymphoid, innate cells in IFN-γ-mediated protection cannot be excluded, a
protective role for macrophage-derived IFN-γ against intracellular bacterial infections
has not been previously described in vivo.
Both CD4+ and CD8+ T cells produce IFN-γ in response to C. trachomatis and
are probably complementary in warranting protective levels of IFN-γ during infection
(reviewed in (301)). But although adaptive immune protection against C. trachomatis
in mice can be demonstrated, for example, by transfer of Chlamydia-specific CD4+ or
CD8+ T cells, there is some degree of controversy regarding the level of protection
conferred by each subset (reviewed in (299, 300)) with some studies suggesting that
CD4+ are more protective than CD8+ T cells. During C. pneumoniae infection both
CD4+ cells and CD8+ cells mediate protection, albeit with a different kinetics where
CD8+ are clearly protective earlier during infection but CD4+ seem to act later (Paper I).
Antibody-depletion studies also support a protective role for CD8+ cells during primary
and particularly during re-infection (376). In line, both CD4+ T cells and CD8+ T cells
are required for (partial) protection against C. pneumoniae by DNA vaccination, an
effect with requires IFN-γ (377). IFN-γ release by T cells has also been associated to
the protective ability of DNA vaccines against C. trachomatis (378, 379). Further,
reconstitution of RAG-1-/-/γcR-/- mice with WT but not IFN-γ-/- CD4+ or CD8+ T cells
protected them against C. pneumoniae infection (Paper III), confirming a protective
role for IFN-γ-producing T cells during C. pneumoniae infection. Of interest,
RAG-1-/-/γcR-/- mice do possess the ability to secrete normal levels of innate IFN-γ,
indicating that T cell-derived and non-lymphoid-derived IFN-γ mediate non-redundant
effects (Paper III). Although IFN-γ has been shown to be involved in triggering T cells
(380), it was also shown that in absence of innate IFN-γ, CD4+ and CD8+ T cells could
still mediate protection through their ability to release IFN-γ (Paper III).
Lysis of cells containing intracellular RBs would be an attractive way to
interfere with infection since this form is not infectious. However, Perforin-/-, Fas-/- and
Fas-ligand-/- mice do not display enhanced susceptibility to C. trachomatis infection
(381). The same is observed in Perforin-/- mice infected with C. pneumoniae  (Paper I).
On the other hand, Chlamydia-specific or naïve CD8+ T cells derived from IFN-γ-/-
mice, failed to provide protection under conditions where the WT CD8+ T cells did
(382), further confirming a role for IFN-γ release in CD8+ T-cell-mediated resistance to
Chlamydia.
T-cell recognition of infected cells may lead to secretion of IFN-γ that mediates
restriction of intracellular Chlamydial growth. In this respect, C. trachomatis has been
shown to suppress IFN-γ-inducible MHC class II expression via degradation of
Upstream stimulatory factor (USF)-1, a constitutively and ubiquitously expressed
transcription factor required for IFN-γ-dependent induction of CIITA (383). Similarly,
C. trachomatis-induced IFN-β has been suggested to mediate the inhibition of
IFN-γ-dependent expression of MHC class II (384). The ability to degrade USF-1 was
mediated by secretion into the cell cytosol of a Chlamydia-derived protease which
turned out to degrade RFX5 as well, a transcription factor required for both constitutive
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and IFN-γ-inducible MHC class I expression (385). A homologue of the C. trachomatis
protease has been found in C. pneumoniae and it too, degrades RFX5 (386). These
evasion strategies clearly confirm the protective role of T cells and IFN-γ against
Chlamydia infections.
In summary, IFN-γ production by both T cells and innate immune cells seems
to be not only important but also complementary for protection against C. pneumoniae.
The combined data suggests that innate release of IFN-γ is required earlier
(approximately 1 to 2 weeks) during infection, while T-cell-derived IFN-γ production is
required much later (approximately 3 weeks) for protection. This is also supported by
the fact that innate IFN-γ was not required for the protective, IFN-γ-dependent actions
of T cells (Paper III) and that differences in C. pneumoniae levels between WT and
RAG-1-/- mice were also only observed 3 weeks after infection. The innate, probably
macrophage-derived IFN-γ, restricts initial bacterial growth and prevents systemic
dissemination while CD4+ or CD8+ T-cell-derived IFN-γ is needed later for bringing
down bacterial levels and thus for resolution of infection.
C. pneumoniae Pattern Recognition in Macrophages
Regulation of IFN-γ in C. pneumoniae-Infected Macrophages (Paper IV, Figure 6)
With support for macrophage-derived IFN-γ during C. pneumoniae lung
infection (Paper III), it may not be surprising that BMMφ were found to express IFN-γ
at the mRNA and protein level, early and transiently after in vitro infection with
C. pneumoniae as well. While the vast majority of findings regarding myeloid IFN-γ
production have implied an IL-12-dependent pathway (discussed under Regulation of
IFN-γ Production: Myeloid IFN-γ), this was one of the first reports suggesting instead
an IFN-α/β-dependent production of IFN-γ. A previous report suggested that
endogenous IFN-α/β primed macrophages for IFN-γ expression following LPS
Figure 6: Role of IFN-α/β in C. pneumoniae Growth Restriction. Infection of macrophages with
C. pneumoniae (1) leads to expression of IFN-α (2). IFN-α/βR signaling regulates expression of
IFN-γ (3) and iNOS (5) both which mediate restriction of bacterial growth (4 and 6).
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stimulation (387). More recent findings also support a role for IFN-α/β in inducting
IFN-γ in DCs (388), probably involving IL-15 as well (389). The fact that IFN-α/β can
inhibit IL-12 expression (185) may account for the low levels of IL-12 recorded in
C. pneumoniae-infected BMMφ, possibly inadequate for induction of IFN-γ.
Alternatively, infection-induced IL-10 was shown to inhibit IL-12 but not IFN-α/β or
iNOS expression, and to reduce the duration of IFN-γ expression, suggesting that IL-10
may prevent an IL-12-dependent pathway of IFN-γ expression, as the in vivo situation
(Paper II & A. Gigliotti Rothfuchs, unpublished observations). The inhibitory role of
IL-10 in IL-12-dependent IFN-γ release by macrophages has been reported by others
(207, 213, 214).
Increased iNOS and NO production in C. pneumoniae-infected BMMφ was
IFN-α/β-dependent but IFN-γ-independent, and important for restricting Chlamydial
growth. It is unclear why IFN-γ was not required for iNOS induction in BMMφ as is
the case in C. pneumoniae-infected mice (Paper I), though studies in C. trachomatis-
infected fibroblasts also show a role for infection-induced IFN-α/β in inducing NO
(390). IFN-α/β-dependent iNOS induction has also been recorded in L. major-infected
BMMφ (98). Such IFN-α/β-dependent NO production has been shown to mediate early
containment of L. major in vivo (391).
While IFN-γ was shown to mediate protective effect(s) in an iNOS-independent
way, the mechanism is unknown. IDO has not clearly been shown to be protective in
mouse cells, and its expression was not detected in C. pneumoniae-infected BMMφ.
Still, a role for IDO in IFN-γ-dependent Chlamydial growth control in BMMφ cannot
be excluded. As discussed for C. pneumoniae lung infection, GTPases and P2X7R
signaling are two potential candidates for IFN-γ-dependent protective effects.
TLRs in Regulation of IFN-α/β-Dependent IFN-γ Expression in
C. pneumoniae-Infected Macrophages (Paper IV)
TLRs can trigger IFN-α/β expression in the presence of MyD88 (via TLR7 (21)
and TLR9 (392)) or in the absence of MyD88 using TRIF (via TLR3 and TLR4 (53))
and TRAM (TLR4 (56)). It was therefore surprising that expression of IFN-α in
C. pneumoniae-infected BMMφ was dependent on TLR4 and MyD88 signaling (Paper
V). Though TLR9 signaling induces IFN-α in a MyD88-dependent fashion, TLR9-/-
BMMφ were not more susceptible to infection, suggesting that expression of IFN-α in
such BMMφ is probably intact (Paper V, data not shown). TLR7 also signals via
MyD88 but because it lacks a natural ligand(s) and has not yet been implicated in
pattern recognition, it is difficult to speculate its involvement in
C. pneumoniae-induced IFN-α expression. Although the presence of a TLR4-mediated,
MyD88-independent pathway cannot be excluded, it clearly is not sufficient to induce
IFN-α responsive-genes in these cells. Only TLR3 and TLR4 have been described to
date as having MyD88-independent signaling. Because no report has been made
concerning the presence of dsRNA in Chlamydia, TLR3 is an unlikely candidate for
mediating Chlamydia pattern recognition. Similarly, whether TLRs other than TLR2,
TLR4, TLR6 or TLR9 also participate in C. pneumoniae-induced IFN-α expression
remains to be explored.
Another finding at variance with other reports was the requirement of STAT1
signaling in IFN-γ expression by BMMφ (Paper V). STAT1 is clearly implicated in
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signaling downstream of both the IFN-α/βR and IFN-γR (discussed under IFN-α/βR
and IFN-γR Signaling) but its requirement for actual IFN-γ expression is not clear. One
report suggests that STAT1 inhibits rather than stimulates IFN-α/β-dependent IFN-γ
production in NK and T cells (233). Signaling by the γcR was also implicated in
IFN-α/β-dependent IFN-γ expression in C. pneumoniae-infected BMMφ and IFN-α/βR
signaling was required for IL-15 expression, a cytokine that signals through the γcR
(Paper V). In line, it has recently been shown that IL-15 and IL-21 (another cytokine
that signals through the γcR) activated the binding of STATs, including STAT1, STAT3
and STAT4 to regulatory sites on the IFN-γ gene in NK and T cells (393). It seems
possible then that IFN-α/β-induced IL-15 activates via the γcR, direct
STAT1-dependent activation of IFN-γ transcription.
Activation of NF-κB and Expression of Pro-inflammatory Cytokines (Paper V)
Activation of NF-κB seems to occur independently of TLR4 and MyD88 in
C. pneumoniae-infected BMMφ, suggesting the involvement of a TLR-independent
pathway of NF-κB activation in these cells. Interestingly, NF-κB-dependent expression
of pro-inflammatory cytokines IL-1α, IL-6 and TNF-α did not require TLR4 or
MyD88 in C. pneumoniae-infected BMMφ. The involvement of other TLRs in
MyD88-independent, pro-inflammatory cytokine expression seems also unlikely since
expression of pro-inflammatory cytokines is abolished in MyD88-/- cells following
stimulation with specific TLR ligands (41, 394). However, this is not formally excluded
as other TLRs not requiring MyD88 may yet be characterized. Though TRIF-/- and
TRAM-/- mice reveal a role for these adaptors in LPS-driven induction of
pro-inflammatory cytokines (53, 56), this is irrelevant in C. pneumoniae-infected
BMMφ since TLR4 itself is not required for pro-inflammatory cytokine expression.
An alternative, TLR-independent pathway for PAMP recognition with ensuing
NF-κB activation and production of pro-inflammatory cytokines has recently been
Figure 7: Molecular Pathways Controlling Macrophage Secretion of IFN-γ after Infection with
C. pneumoniae. IFN-γ expression is regulated by a TLR4-MyD88-STAT1 pathway and by a
TLR4-independent pathway leading to NF-κB activation.
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suggested to be mediated by the Nucleotide-binding oligomerization domain (NOD)
family of proteins (reviewed in (395)). Peptidoglycans are present in all bacteria and
NOD1 has been shown to recognize peptidoglycans from Gram-negative bacteria while
NOD2 can recognize peptidoglycans from all bacteria (reviewed in (396)). The role of
NOD1 and NOD2 in Chlamydia pattern recognition is unknown. Preliminary data from
our laboratory suggests however that treatment of C. pneumoniae-infected BMMφ with
cytochalasin D, an inhibitor of phagocytosis, does not affect expression of
pro-inflammatory cytokines or activation of NF-κB but blocks IFN-α and IFN-γ
expression. This is in line with results where antibiotic-treatment of BMMφ reduced
IFN-α and IFN-γ but not the pro-inflammatory response (Paper IV & data not shown).
This suggests that intracellular recognition is not required for NF-κB activation and
consequent induction of pro-inflammatory cytokines. However, phagocytosis and
viable bacteria are required for C. pneumoniae-induced, TLR-dependent IFN-α
expression. The inflammatory response to C. pneumoniae remains therefore enigmatic
(Figure 7).
IFN-α/β in Resistance to C. pneumoniae Lung Infection (Paper VI)
The unaltered (or possibly even reduced) susceptibility of IFN-α/βR-/- mice to
C. pneumoniae infection does not relate to the in vitro data showing enhanced
Chlamydial growth in IFN-α/βR-/- BMMφ. Although administration of exogenous
IFN-α/β or inducers thereof, have protected or ameliorated disease in mice infected
with intracellular bacteria (397, 398), intracellular protozoa (399-401), or fungi (402), a
protective role for endogenous IFN-α/β during non-viral infections has only been
documented early during L. major infection (391) and during a low-dose infection with
M. tuberculosis in IFN-α/βR-/- mice (403). However, endogenous IFN-α/β does
participate together with IFN-γ  in protection against C. pneumoniae, as demonstrated
by the enhanced susceptibility of IFN-α/βR-/-/IFN-γR-/- mice compared with IFN-γR-/-
mice. This observation, together with the previous findings in L. major and
M. tuberculosis, constitute the only supportive data on a protective role for endogenous
IFN-α/β during non-viral, experimental infections. The cooperative, protective effect of
IFN-α/β and IFN-γ are probably mediated through activation of STAT1. Such a
positive cross-talk between IFN-α/β and IFN-γ at the level of STAT1 is well described
and feasible since STAT1 is important for signaling downstream of both the IFN-γR
and the IFN-α/βR (discussed under IFN-α/βR and IFN-γR Signaling, and reviewed in
(404)). The protective effect mediated by IFN-α/β is however, only evident in the
absence of IFN-γ.
The reason why IFN-α/β are pivotal in regulating protective responses in
BMMφ, including the release of IFN-γ, but in vivo are not required for IFN-γ
expression (which is largely IL-12-dependent) and seem only secondary to
IFN-γ-mediated protection, is currently unknown. This discrepancy may be a
qualitative feature in C. pneumoniae pattern recognition by different cell types. In vivo,
the different cell types in the lung convey the generation of protective, IL-12-driven
responses, while in vitro, IFN-α/β-driven protection in BMMφ are essential. In line,
bone marrow-derived DCs infected in vitro with C. pneumoniae express IFN-γ in the
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absence of IFN-α/βR signaling and could therefore fit in with the IL-12-biased
pathway of IFN-γ release which seems to dominate in vivo (Paper II).
CONCLUDING REMARKS
Implications for Vaccine Design
Asymptomatic or mild, clinical disease ensues in most cases of C. pneumoniae
infection, as is the case for C. trachomatis. For C. trachomatis though, serious
pathological complications to otherwise mild/asymptomatic infection occur in the form
of blindness from trachoma or infertility and ectopic pregnancy from salpingitis
(reviewed in (236, 307)). The association of C. pneumoniae infection to chronic
obstructive lung disease, asthma and atherosclerosis become therefore even more
impending since more than 50% of the population worldwide are sero-positive for
C. pneumoniae. A vaccine against either C. trachomatis or C. pneumoniae would
therefore not only reduce the incidence of clinical disease (trachoma, salpingitis, CAP
and upper respiratory disease) but also, and equally important, reduce the incidence of
the severe pathological complications of Chlamydia infection. This is particularly
important considering the link between C. pneumoniae and atherosclerosis.
The sensitization to a more severe disease in individuals vaccinated against
C. trachomatis (reviewed in (236)) suggests that failing to first understand the immune
response to Chlamydia may consequently lead to failure in vaccine design. Since TLR
ligands essentially mediate adjuvant effects such as co-stimulation and cytokine
release, understanding the fine molecular details of pattern recognition might facilitate
at some point, the selective mustering of a host response, through the use of a particular
PAMP, natural or modified for the purpose of inducing that wanted response. The only
partial protection obtained in experimental vaccines with Chlamydial antigens clearly
suggest that appropriate antigens must first be identified for a vaccine to be optimal.
Vaccination would also need to avoid generating persistence. It is not clear how this
will be achieved but vaccination strategies will in any case require the generation of
ample, adaptive IFN-γ responses for protection.
General Conclusions
A set of basic conclusions can be drawn from the papers presented in this thesis
and are summarized below:
1) IFN-γ restricts C. pneumoniae growth.
2) Innate-immune cells are an important source of IFN-γ and macrophages
(but not NK cells) are involved in IFN-γ release.
3) CD4+ and CD8+ cells have a protective role that depends on their
capacity to secrete IFN-γ. T-cell-derived IFN-γ plays a protective role at
late times during primary infection, synergizes in protection with non-
lymphoid IFN-γ, but is not dependent on the latter for protection.
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4) IFN-γ-independent mechanisms also contribute in the control of
infection.
5) IL-12/IL-23 regulates expression of IFN-γ in vivo.
6) IFN-α/β is not required for IFN-γ expression in vivo but restricts
C. pneumoniae growth in a STAT1-dependent way in the absence of
IFN-γ.
7) IFN-α/β is important for restricting C. pneumoniae growth in
macrophages by regulating expression of IFN-γ and iNOS, in a
STAT1-dependent manner.
8) TLR4 and MyD88 are required for IFN-α expression in
C. pneumoniae-infected macrophages but not for activation of NF-κB
and expression of pro-inflammatory cytokines.
9) NF-κB is required for expression of IFN-γ in C. pneumoniae-infected
macrophages.
10) Working with Chlamydia is fun!
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